



03-27-06

1fw

Express Mail No. EQ530501463US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Lawrence L. Kunz	Confirmation No.:	1075
Serial No.:	09/590,002	Art Unit:	1621
Filed:	June 8, 2000	Examiner:	Samuel A. BARTS
For:	THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS	Attorney Docket No.:	10177-216-999
		CAM No.:	008563-999213

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information that the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:

- 1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.
- 1b. A legible copy of :
 - ☒ Each publication or that portion which caused it to be listed on the PTO-1449;
 - ☐ For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion that have been checked to be unavailable at the USPTO's private PAIR system;
 - ☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report;
 - ☒ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications;
 - ☒ All other information or portion which caused it to be listed on the PTO-1449.
- 1c. ☒ Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith unless required by the office.
- 1d. ☐ Pursuant to 1287 OG 163, copies of cited pending unpublished applications that are available at the USPTO's private PAIR system are not submitted herewith.

- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
- ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
- ☐ Before the mailing of the first Office action on the merits;
- ☒ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

3. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☐ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed.
 - ☐ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Jones Day Deposit Account No. 50-3013.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked):

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.

6. ☒ This application is a continuation application under 37 C.F.R. §1.53(b) or (d).

(Check appropriate Items 6a, 6b and/or 6c)

- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☒ Copies of publications listed on Form PTO-1449 from prior application Serial No. 08/389,712, filed on February 15, 1995, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☒ Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. 08/389,712, filed on February 15, 1995, and are provided herewith.

7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)

- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .

8. ☒ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 8a, 8b, or 8c)

- 8a. ☐ Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.

- 8b. ☐ Set forth in the application.


- 8c. ☒ Enclosed as an attachment hereto.

9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.

10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: March 23, 2006



Gidon D. Stern

(Reg. No. 27,469)

By:



Linda B. Azrin

(Reg. No. 44,516)


JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures



Express Mail No. EQ530501463US

Sheet 1 of 32

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.
10177-216-999

APPLICATION NO.
09/590,002

APPLICANT
Lawrence L. Kunz

FILING DATE
June 8, 2000

GROUP
1621

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,783,543	08/31/04	Jang			
	A02	6,764,507	07/20/04	Shanley, et al.			
	A03	6,689,159	02/10/04	Lau, et al.			
	A04	6,663,881	12/16/03	Kunz, et al.			
	A05	6,656,216	12/02/03	Nossainy, et al.			
	A06	6,656,162	12/02/03	Santini Jr., et al.			
	A07	6,616,765	09/09/03	Castro, et al.			
	A08	6,616,690	09/09/03	Rolando, et al.			
	A09	6,599,928	07/29/03	Kunz, et al.			
	A10	6,596,022	07/22/03	Lau, et al.			
	A11	6,575,993	07/10/03	Yock			
	A12	6,562,065	05/13/03	Shanley			
	A13	6,555,138	04/29/03	Karlsson			
	A14	6,544,790	04/08/03	Sabatini			
	A15	6,544,544	04/08/03	Hunter, et al.			
	A16	6,527,789	03/04/03	Lau, et al.			
	A17	6,497,647	12/24/02	Tucker			
	A18	6,492,106	12/10/02	Sabatini et al.			
	A19	6,491,617	12/10/02	Ogle, et al.			
	A20	6,488,694	12/03/02	Lau, et al.			
	A21	6,485,511	11/26/02	Lau, et al.			
	A22	6,476,200	11/05/02	Sabatini, et al.			
	A23	6,461,381	10/08/02	Israel, et al.			
	A24	6,443,982	09/03/02	Israel, et al.			
	A25	6,432,133	08/13/02	Lau, et al.			
	A26	6,429,232	08/06/02	Kinsella, et al.			
	A27	6,395,326	05/28/02	Castro, et al.			
	A28	6,309,414	10/30/01	Rolando, et al.			
	A29	6,309,412	10/30/01	Lau, et al.			
	A30	6,251,920	06/26/01	Grainger, et al.			
	A31	6,241,762	06/05/01	Shanley			
	A32	6,210,393	04/03/01	Briskin, et al.			
	A33	6,203,536	03/20/01	Berg, et al.			
	A34	6,198,016	03/06/01	Lucast, et al.			
	A35	6,187,370	02/13/01	Dinh, et al.			

	A36	6,168,619	01/02/01	Dinh, et al.			
	A37	6,152,869	11/28/00	Park, et al.			
	A38	6,146,358	11/14/00	Rowe			
	A39	6,133,242	10/17/00	Zalewski, et al.			
	A40	6,129,757	10/10/00	Weadock			
	A41	6,120,536	09/19/00	Ding, et al.			
	A42	6,110,483	08/29/00	Whitbourne, et al.			
	A43	6,106,454	08/22/00	Berg, et al.			
	A44	6,099,562	08/08/00	Ding, et al.			
	A45	6,099,499	08/08/00	Ciamacco, et al.			
	A46	6,096,070	08/01/00	Ragheb, et al.			
	A47	6,093,142	07/25/00	Kunz, et al.			
	A48	6,086,910	07/11/00	Howard, et al.			
	A49	6,074,659	06/13/00	Kunz, et al.			
	A50	6,074,337	06/13/00	Tucker et al.			
	A51	6,066,167	05/23/00	Lau, et al.			
	A52	6,042,875	03/28/00	Ding, et al.			
	A53	6,036,715	03/14/00	Yock			
	A54	6,033,866	02/08/00	Falk, et al.			
	A55	6,013,099	01/11/00	Dinh, et al.			
	A56	6,001,622	12/14/99	Dedhar, et al.			
	A57	5,990,095	11/23/99	Falk, et al.			
	A58	5,980,972	11/09/99	Ding			
	A59	5,972,018	10/26/99	Israel, et al.			
	A60	5,948,639	09/07/99	Ginemo, et al.			
	A61	5,945,456	08/31/99	Grainger, et al.			
	A62	5,902,332	05/11/99	Schatz			
	A63	5,900,246	05/04/99	Lambert			
	A64	5,877,224	03/02/99	Brocchini, et al.			
	A65	5,873,904	02/23/99	Ragheb, et al.			
	A66	5,863,285	01/26/99	Coletti			
	A67	5,849,034	12/15/98	Schwartz			
	A68	5,843,120	12/01/98	Israel, et al.			
	A69	5,837,313	11/17/98	Ding, et al.			
	A70	5,837,008	11/17/98	Berg, et al.			
	A71	5,824,647	10/20/98	Postlethwaite, et al.			
	A72	5,824,054	10/20/98	Khosravi, et al.			
	A73	5,824,049	10/20/98	Ragheb, et al.			
	A74	5,824,048	10/20/98	Tuch			
	A75	5,821,234	10/13/98	Dzau			
	A76	5,811,447	09/22/98	Kunz, et al.			
	A77	5,800,507	09/01/98	Schwartz			
	A78	5,797,898	08/25/98	Santini Jr., et al.			
	A79	5,779,732	07/14/98	Amundson			
	A80	5,776,184	07/07/98	Tuch			

	A81	5,770,609	06/23/98	Grainger, et al.			
	A82	5,767,079	06/16/98	Glaser, et al.			
	A83	5,749,915	05/12/98	Slepian			
	A84	5,749,888	05/12/98	Yock			
	A85	5,747,510	05/05/98	Draper			
	A86	5,735,897	04/07/98	Buirge			
	A87	5,733,303	03/31/98	Israel, et al.			
	A88	5,731,424	03/24/98	Toothman, et al.			
	A89	5,731,200	03/24/98	Ichijo, et al.			
	A90	5,731,144	03/24/98	Toothman, et al.			
	A91	5,726,186	03/10/98	Grese			
	A92	5,722,984	03/03/98	Fischell, et al.			
	A93	5,705,609	01/06/98	Ruoslahti, et al.			
	A94	5,705,477	01/06/98	Sporn, et al.			
	A95	5,700,559	12/23/97	Sheu, et al.			
	A96	5,697,967	12/16/97	Dinh, et al.			
	A97	5,693,607	12/02/97	Segrini, et al.			
	A98	5,688,855	11/18/97	Stoy, et al.			
	A99	5,688,813	11/18/97	Sall, et al.			
	A100	5,686,476	11/11/97	May			
	A101	5,686,467	11/11/97	Bumol, et al.			
	A102	5,681,835	10/28/97	Willson			
	A103	5,679,400	10/21/97	Tuch			
	A104	5,677,295	10/14/97	Failli, et al.			
	A105	5,667,764	09/16/97	Kopia, et al.			
	A106	5,662,712	09/02/97	Pathak, et al.			
	A107	5,658,951	08/19/97	Magarian, et al.			
	A108	5,658,927	08/19/97	Magarian, et al.			
	A109	5,658,883	08/19/97	Ogawa, et al.			
	A110	5,656,587	08/12/97	Sporn, et al.			
	A111	5,656,450	08/12/97	Boyan, et al.			
	A112	5,652,259	07/29/97	May			
	A113	5,651,627	07/29/97	Dowzall, et al.			
	A114	5,643,580	07/01/97	Subramanian			
	A115	5,641,790	06/24/97	Draper			
	A116	5,639,738	06/17/97	Falk, et al.			
	A117	5,639,274	06/17/97	Fischell, et al.			
	A118	5,637,113	06/10/97	Tartaglia, et al.			
	A119	5,635,489	06/03/97	Haley			
	A120	5,632,840	05/27/97	Campbell			
	A121	5,629,077	05/13/97	Turnlund, et al.			
	A122	5,626,600	05/06/97	Horzewski, et al.			
	A123	5,622,975	04/22/97	Singh, et al.			
	A124	5,610,168	03/11/97	Draper			
	A125	5,610,166	03/11/97	Singh			

	A126	5,607,463	03/04/97	Schwartz, et al.			
	A127	5,605,700	02/25/97	DeGregorio, et al.			
	A128	5,605,696	02/25/97	Eury, et al.			
	A129	5,599,844	02/04/97	Grainger, et al.			
	A130	5,597,578	01/28/97	Brown, et al.			
	A131	5,595,722	11/21/97	Grainger, et al.			
	A132	5,591,224	01/07/97	Schwartz, et al.			
	A133	5,578,703	11/16/96	Ichijo, et al.			
	A134	5,578,075	11/26/96	Dayton			
	A135	5,574,047	11/12/96	Bumol, et al.			
	A136	5,571,808	11/05/96	Leeds			
	A137	5,571,714	11/05/96	Dasch, et al.			
	A138	5,571,166	11/05/96	Dinh, et al.			
	A139	5,569,463	10/29/96	Helmus, et al.			
	A140	5,567,713	10/22/96	Cullinan, et al.			
	A141	5,563,145	10/08/96	Failli, et al.			
	A142	5,563,054	10/08/96	Briggs, et al.			
	A143	5,562,922	10/08/96	Lambert			
	A144	5,556,876	09/17/96	Bryant, et al.			
	A145	5,554,182	09/10/96	Dinh, et al.			
	A146	5,552,433	09/03/96	Bryant, et al.			
	A147	5,552,415	09/03/96	May			
	A148	5,551,954	09/03/96	Buscemi, et al.			
	A149	5,545,569	08/13/96	Grainger, et al.			
	A150	5,545,409	08/13/96	Laurencin, et al.			
	A151	5,545,208	08/13/96	Wolff, et al.			
	A152	5,543,155	08/06/96	Fekete, et al.			
	A153	5,541,174	07/30/96	Sorenson			
	A154	5,538,892	06/23/96	Donahoe, et al.			
	A155	5,534,527	07/09/96	Black, et al.			
	A156	5,525,624	06/11/96	Gitter, et al.			
	A157	5,525,610	06/11/96	Caufield, et al.			
	A158	5,523,092	06/04/96	Hanson, et al.			
	A159	5,521,198	05/28/96	Zuckerman			
	A160	5,521,172	05/28/96	Bryant, et al.			
	A161	5,521,171	05/28/96	Sorenson			
	A162	5,514,154	05/07/96	Lau, et al.			
	A163	5,512,268	04/30/96	Grinstaff, et al.			
	A164	5,510,370	04/23/96	Hock, et al.			
	A165	5,510,077	04/23/96	Dinh, et al.			
	A166	5,508,292	04/16/96	Sall, et al.			
	A167	5,504,091	04/02/96	Molnar-Kimber, et al.			
	A168	5,500,013	03/19/96	Buschemi, et al.			
	A169	5,496,851	03/05/96	Grinnell			
	A170	5,496,828	03/05/96	Cullinan			

	A171	5,496,581	03/05/96	Yianni, et al.			
	A172	5,496,557	03/05/96	Feijen, et al.			
	A173	5,496,346	03/05/96	Horzewski, et al.			
	A174	5,492,927	02/20/96	Gitter, et al.			
	A175	5,492,926	02/20/96	Cullinan, et al.			
	A176	5,492,922	02/20/96	Palkowitz			
	A177	5,492,921	02/20/96	Bryant, et al.			
	A178	5,492,895	02/20/96	Vlasuk, et al.			
	A179	5,491,173	02/13/96	Toivola, et al.			
	A180	5,491,159	02/13/96	Malamas			
	A181	5,489,587	02/06/96	Fontana			
	A182	5,486,357	01/23/96	Narayanan			
	A183	5,484,808	01/16/96	Grinell			
	A184	5,484,798	01/16/96	Bryant, et al.			
	A185	5,484,797	01/16/96	Bryant, et al.			
	A186	5,484,796	01/16/96	Bryant, et al.			
	A187	5,484,795	01/16/96	Bryant, et al.			
	A188	5,482,950	01/09/96	Bryant, et al.			
	A189	5,482,949	01/09/96	Black, et al.			
	A190	5,482,851	01/09/96	Derynck, et al.			
	A191	5,480,904	01/02/96	Bryant, et al.			
	A192	5,480,903	01/02/96	Piggott, et al.			
	A193	5,480,888	01/02/96	Kodama, et al.			
	A194	5,478,847	12/26/95	Draper			
	A195	5,472,985	12/05/95	Grainger, et al.			
	A196	5,470,883	11/28/95	Stromberg			
	A197	5,470,876	11/28/95	Proctor			
	A198	5,466,810	11/14/95	Godfrey			
	A199	5,464,450	11/07/95	Buscemi, et al.			
	A200	5,462,966	10/31/95	Sofia			
	A201	5,462,950	10/31/95	Fontana			
	A202	5,462,949	10/31/95	Jones, et al.			
	A203	5,462,937	10/31/95	Cullinan, et al.			
	A204	5,461,065	10/24/95	Black, et al.			
	A205	5,461,064	10/24/95	Cullinan, G.J.			
	A206	5,457,117	10/10/95	Black, et al.			
	A207	5,457,116	10/10/95	Black, et al.			
	A208	5,457,113	10/10/95	Cullinan, et al.			
	A209	5,455,275	10/03/95	Fontana			
	A210	5,453,492	09/26/95	Butzow, et al.			
	A211	5,451,603	09/19/95	Piggott			
	A212	5,451,590	09/19/95	Dodge			
	A213	5,451,589	09/19/95	Dodge			
	A214	5,451,414	09/19/95	Steward			
	A215	5,451,233	09/19/95	Yock			

	A216	5,449,382	09/12/95	Dayton			
	A217	5,447,941	09/05/95	Zuckerman			
	A218	5,447,724	09/05/95	Helmus, et al.			
	A219	5,446,070	08/29/95	Mantelle			
	A220	5,446,053	08/29/95	Keohane			
	A221	5,445,941	08/29/95	Yang			
	A222	5,444,164	08/22/95	Purchio, et al.			
	A223	5,443,458	08/22/95	Eury			
	A224	5,441,986	08/15/95	Thompson			
	A225	5,441,966	08/15/95	Dodge			
	A226	5,441,965	08/15/95	Sall, et al.			
	A227	5,441,964	08/15/95	Bryant, et al.			
	A228	5,441,734	08/15/95	Reichert, et al.			
	A229	5,439,931	08/08/95	Sales			
	A230	5,439,923	08/08/95	Cullinan			
	A231	5,439,689	08/08/95	Hendrickson, et al.			
	A232	5,436,243	07/25/95	Sachs, et al.			
	A233	5,434,166	07/18/95	Glasebrook			
	A234	5,429,618	07/04/95	Keogh			
	A235	5,426,123	06/20/95	Fontana			
	A236	5,424,331	06/13/95	Shlyankevich			
	A237	5,421,955	06/06/95	Lau, et al.			
	A238	5,420,243	05/30/95	Ogawa, et al.			
	A239	5,419,760	05/30/95	Narciso, Jr.			
	A240	5,418,252	05/23/95	Williams			
	A241	5,416,205	05/16/95	Della Valle, et al.			
	A242	5,415,619	05/16/95	Lee, et al.			
	A243	5,411,988	05/02/95	Bockow, et al.			
	A244	5,411,967	05/02/95	Kao, et al.			
	A245	5,401,730	03/28/95	Sauvage, et al.			
	A246	5,399,352	03/21/95	Hanson			
	A247	5,395,842	03/07/95	Labrie, et al.			
	A248	5,393,785	02/28/95	Labrie, et al.			
	A249	5,393,763	02/28/95	Black, et al.			
	A250	5,391,557	02/21/95	Cullinan, et al.			
	A251	5,391,378	02/21/95	Sanderson			
	A252	5,389,670	02/14/95	Fontana			
	A253	5,387,680	02/07/95	Nelson			
	A254	5,384,332	01/24/95	Fontana			
	A255	5,383,928	01/24/95	Scott, et al.			
	A256	5,380,299	01/10/95	Fearnot, et al.			
	A257	5,378,475	01/03/95	Smith, et al.			
	A258	5,362,718	11/08/94	Skotnicki, et al.			
	A259	5,362,478	11/08/94	Desai, et al.			
	A260	5,356,433	10/18/94	Rowland, et al.			

	A261	5,340,925	08/23/94	Lioubin, et al.			
	A262	5,338,770	08/16/94	Winters, et al.			
	A263	5,332,576	07/26/94	Mantelle			
	A264	5,324,736	06/08/94	Magarin, et al.			
	A265	5,318,779	06/07/94	Hakamatsuka, et al.			
	A266	5,308,889	05/03/94	Rhee, et al.			
	A267	5,304,541	04/19/94	Purchio, et al.			
	A268	5,304,121	04/19/94	Sahatjian			
	A269	5,302,584	04/12/94	Kao, et al.			
	A270	5,292,802	03/08/94	Rhee, et al.			
	A271	5,290,271	03/01/94	Jernberg			
	A272	5,284,763	02/08/94	Derynk, et al.			
	A273	5,282,823	02/01/94	Schwartz, et al.			
	A274	5,280,109	01/18/94	Miyazono et al.			
	A275	5,280,040	01/18/94	Labroo, et al.			
	A276	5,262,451	11/16/93	Winters, et al.			
	A277	5,262,319	11/16/93	Iwata, et al.			
	A278	5,258,020	11/02/93	Froix			
	A279	5,254,594	10/19/93	Niikura, et al.			
	A280	5,252,579	10/12/93	Skotnicki, et al.			
	A281	5,238,714	08/24/93	Wallace, et al.			
	A282	5,234,957	08/10/93	Mantelle			
	A283	5,229,495	07/20/93	Ichijo, et al.			
	A284	5,226,913	07/13/93	Pinchuk			
	A285	5,222,971	06/29/93	Willard, et al.			
	A286	5,221,620	06/22/93	Purchio, et al.			
	A287	5,219,548	06/15/93	Yang, et al.			
	A288	5,216,126	06/01/93	Cox, et al.			
	A289	5,216,021	06/01/93	Sorenson			
	A290	5,211,940	05/18/93	Ishiguro, et al.			
	A291	5,199,951	04/06/93	Spears			
	A292	5,195,984	03/23/93	Schatz			
	A293	5,192,525	03/09/93	Yang, et al.			
	A294	5,189,212	02/23/93	Ruenitz			
	A295	5,189,046	02/23/93	Burch, et al.			
	A296	5,185,408	02/09/93	Tang, et al.			
	A297	5,182,317	01/26/93	Winters, et al.			
	A298	5,180,376	01/19/93	Fischell			
	A299	5,163,952	11/17/92	Froix			
	A300	5,145,838	09/08/92	Pickart			
	A301	5,145,684	09/08/92	Liversidge, et al.			
	A302	5,126,348	06/30/92	McMurray.			
	A303	5,120,535	06/09/92	Marguardt, et al.			
	A304	5,118,791	06/02/92	Burnier, et al.			
	A305	5,108,989	05/28/92	Amento, et al.			

	A306	5,102,417	04/07/92	Palmaz			
	A307	5,100,885	03/31/92	Abrams, et al.			
	A308	5,098,903	03/24/92	Magarian, et al.			
	A309	5,092,877	03/03/92	Pinchuk			
	A310	5,082,834	01/21/92	Sorenson			
	A311	5,075,321	12/24/91	Schreiber			
	A312	5,064,435	11/12/91	Porter			
	A313	5,061,275	10/29/91	Wallsten, et al.			
	A314	5,061,273	10/29/91	Yock			
	A315	5,053,048	10/01/91	Pinchuk, et al.			
	A316	5,047,431	09/10/91	Schickaneder, et al.			
	A317	5,040,548	08/20/91	Yock			
	A318	5,037,641	08/06/91	Juhos, et al.			
	A319	5,034,265	07/23/91	Hoffman, et al.			
	A320	5,023,237	06/11/91	Pickart, et al.			
	A321	5,019,504	05/28/91	Christen, et al.			
	A322	5,015,666	05/14/91	Magarian, et al.			
	A323	5,008,279	04/16/91	Franckowiak, et al.			
	A324	5,002,531	03/26/91	Bonzel			
	A325	4,999,347	03/12/91	Sorenson			
	A326	4,997,652	03/05/91	Wong			
	A327	4,996,225	02/26/91	Toivola, et al.			
	A328	4,994,384	02/19/91	Prather, et al.			
	A329	4,994,071	02/19/91	McGregor			
	A330	4,990,538	02/05/91	Harris, et al.			
	A331	4,990,158	02/05/91	Kaplan, et al.			
	A332	4,984,594	01/15/91	Vinegar, et al.			
	A333	4,973,601	11/27/90	Dowd, et al.			
	A334	4,973,755	11/27/90	Gafe, et al.			
	A335	4,959,355	09/25/90	Fischbarg, et al.			
	A336	4,956,188	09/11/90	Anderson			
	A337	4,954,126	09/04/90	Wallsten			
	A338	4,952,607	08/28/90	Sorenson			
	A339	4,922,905	05/08/90	Strecker			
	A340	4,916,193	04/10/90	Tang, et al.			
	A341	4,900,561	02/13/90	Abdel-Monem, et al.			
	A342	4,886,062	12/12/89	Wiktor			
	A343	4,879,315	11/07/89	Magarian, et al.			
	A344	4,872,867	10/10/89	Joh, et al.			
	A345	4,859,585	08/22/89	Sonnenschein, et al.			
	A346	4,853,377	08/01/89	Pollack,			
	A347	4,840,939	06/20/89	Leveen, et al.			
	A348	4,839,155	06/13/89	McCague			
	A349	4,826,672	05/02/89	Milius, et al.			
	A350	4,824,661	04/25/89	Wagner			

	A351	4,793,348	12/27/88	Palmaz			
	A352	4,786,500	11/22/88	Wong			
	A353	4,776,337	10/11/88	Palmaz			
	A354	4,768,507	09/06/88	Fischell, et al.			
	A355	4,767,758	08/30/88	Breccia, et al.			
	A356	4,762,129	08/09/88	Bonzel			
	A357	4,760,051	07/26/88	Pickart			
	A358	4,758,555	07/19/88	Sorenson			
	A359	4,758,554	07/19/88	Sorenson, et al.			
	A360	4,757,059	07/12/88	Sorenson			
	A361	4,753,652	06/28/88	Langer, et al.			
	A362	4,748,982	06/07/88	Horzewski, et al.			
	A363	4,739,762	04/26/88	Palmaz			
	A364	4,733,665	03/29/88	Palmaz			
	A365	4,732,763	03/22/88	Beck, et al.			
	A366	4,705,647	11/10/87	Yamaguchi, et al.			
	A367	4,696,949	08/29/87	Toivola, et al.			
	A368	4,689,046	08/25/87	Bokros			
	A369	4,687,482	08/18/87	Hanson			
	A370	4,678,466	07/07/87	Rosenwald			
	A371	4,670,428	06/02/87	Sorenson			
	A372	4,657,928	04/14/87	Sorenson			
	A373	4,656,083	04/07/87	Hoffman, et al.			
	A374	4,655,771	04/07/87	Wallsten			
	A375	4,629,694	12/16/86	Harpel			
	A376	4,613,665	09/23/86	Larm			
	A377	4,605,644	08/12/86	Foker			
	A378	4,536,516	08/20/85	Harper, et al.			
	A379	4,491,574	01/01/85	Seifter, et al.			
	A380	4,487,780	12/11/84	Scheinberg			
	A381	4,442,119	04/10/84	Magarian, et al.			
	A382	4,440,754	04/03/84	Sorenson			
	A383	4,428,963	01/31/84	Confalone, et al.			
	A384	4,418,068	11/29/83	Jones			
	A385	4,382,143	05/03/83	Shepherd			
	A386	4,380,635	04/19/83	Peters			
	A387	4,339,429	07/13/82	Raaf, et al.			
	A388	4,332,791	06/01/82	Raaf, et al.			
	A389	4,323,707	04/06/82	Suarez, et al.			
	A390	4,317,915	03/02/82	Confalone, et al.			
	A391	4,315,028	02/09/82	Scheinberg			
	A392	4,310,523	01/12/82	Neumann			
	A393	4,307,111	12/22/81	Crawley			
	A394	4,300,244	11/17/81	Bokros			
	A395	4,292,965	10/06/81	Nash, et al.			

	A396	4,287,190	09/01/81	Boettcher, et al.			
	A397	4,282,246	08/04/81	Holland			
	A398	4,239,778	12/16/80	Venton, et al.			
	A399	4,235,988	11/25/80	Fildes, et al.			
	A400	4,230,862	10/28/80	Suarez, et al.			
	A401	4,221,785	09/09/80	Sorenson			
	A402	4,219,656	08/26/80	Press, et al.			
	A403	4,219,520	08/26/80	Kline			
	A404	4,205,685	06/03/80	Yoshida, et al.			
	A405	4,133,814	01/09/79	Jones, et al.			
	A406	3,952,334	04/27/76	Bokros, et al.			
	A407	3,932,627	01/13/76	Margaf			
	A408	3,879,516	04/22/75	Wolvek			
	A409	3,738,365	06/12/73	Schulte			
	A410	3,634,517	01/11/72	Palopoli, et al.			
	A411	3,526,005	09/01/70	Bokros, et al.			
	A412	3,445,473	05/20/69	Ruschig, et al.			
	A413	3,288,806	11/29/66	Dewald, et al.			
	A414	3,279,996	10/18/66	Long, et al.			
	A415	3,168,565	02/02/65	Palopoli, et al.			
	A416	3,010,965	11/28/61	Elpern			
	A417	2,914,563	11/24/59	Allen, et al.			
	A418	RE 33,403	11/23/90	Stolle, et al.			
	A419	RE 32,944	06/06/89	Harita, et al.			
	A420	2004/0236416	11/25/04	Falotico			
	A421	US 08/526,273	09/11/95	Ding			
	A422	US 07/767,254	09/27/91	Kunz, et al.			
	A423	2002/0032477	03/14/02	Helmus, et al.			
	A424	2002/0091433	07/11/02	Ding, et al.			
	A425	6,515,009	2/04/03	Kunz, et al.			
	A426	5,981,568	11/09/99	Kunz, et al.			
	A427	6,306,421	10/23/01	Kunz, et al.			
	A428	6,074,658	06/13/00	Kunz, et al.			
	A429	6,515,009	02/04/03	Kunz, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	31079/93	07/15/93	Australian Patent Application				
	B02	03-297469	12/27/91	Japan (with English abstract)				
	B03	06-121828	06/05/94	Japan (with English abstract)				
	B04	06-205838	07/26/94	Japan (with English abstract)				
	B05	08-33718	02/06/96	Japan (with English abstract)				
	B06	09-255570	03/21/96	Japan (with English abstract)				
	B07	59-042375	03/08/84	Japan (with English abstract)				

	B08	60-25288	02/01/94	Japan (with English abstract)				
	B09	32-97469	12/27/91	Japan				
	B10	1 015 787	01/05/96	United Kingdom				
	B11	1 587 084	05/25/81	United Kingdom				
	B12	2 273 873	06/07/94	United Kingdom				
	B13	1 205 743	07/15/96	United Kingdom				
	B14	2 153 253	01/25/85	United Kingdom				
	B15	2,086,642	07/10/93	Canada				
	B16	2,231,727	09/14/04	Canada				
	B17	2,079,205	03/26/94	Canada				
	B18	2,086,642	07/10/93	Canada				
	B19	2,207,659	06/13/96	Canada				
	B20	2255063	07/18/75	France				
	B21	4320896	01/05/95	Germany (with English abstract)				
	B22	4320898	01/05/95	Germany (with English abstract)				
	B23	4401554	08/18/94	Germany				
	B24	DE A 3 918 736	12/13/90	Germany (with English abstract)				
	B25	DE A 40 22 956	02/06/92	Germany (with English abstract)				
	B26	1247527	04/24/91	Italy				
	B27	EP 0 095 875 A2	12/07/83	Europe				
	B28	EP 0 002 341	06/13/79	Europe				
	B29	EP 0 024 096	02/25/81	Europe				
	B30	EP 0 054 168 A1	06/23/82	Europe				
	B31	EP 0 260 066 B1	03/16/88	Europe				
	B32	EP 0 374 044 B1	06/20/90	Europe				
	B33	EP 0 551 182 A1	07/14/93	Europe				
	B34	EP 0 566 245 A1	10/20/93	Europe				
	B35	EP 0 604 022 A1	06/29/94	Europe				
	B36	EP 0 621 015 A1	04/23/04	Europe				
	B37	EP 0 623 345 A1	05/03/94	Europe				
	B38	EP 0 701 802 A1	03/20/93	Europe				
	B39	EP 0 706 376 B1	06/25/97	Europe				
	B40	EP 0 716 836 A1	12/11/95	Europe				
	B41	EP 0 734 721 A2	10/02/96	Europe				
	B42	EP 0 975 340	10/08/98	Europe				
	B43	EP 1 360 967 A1	11/12/03	Europe				
	B44	EP A 0 430 542 A2	11/20/90	Europe				
	B45	EP A 0 435 518 B1	12/13/90	Europe				
	B46	EP 0 290 012	11/09/88	Europe				
	B47	EP 0 302 034	02/01/89	Europe				
	B48	EP 0 635 270	01/25/95	Europe				
	B49	EP 0 377 526B1	07/11/90	Europe				
	B50	EP 0 524 093	01/20/93	Europe				
	B51	EP 0 542 679	05/19/93	Europe				
	B52	EP 0 551 182	07/14/93	Europe				
	B53	EP 0 629 697 A3	12/21/94	Europe				

	B54	EP 0 639 577	02/22/95	Europe				
	B55	EP 0 659 413 A2	06/28/95	Europe				
	B56	EP 0 659 415 A2	06/28/95	Europe				
	B57	EP 0 659 418	06/28/95	Europe				
	B58	EP 0 659 419 A1	06/28/95	Europe				
	B59	EP 0 659 429 A1	06/28/95	Europe				
	B60	EP 0 664 121	07/26/95	Europe				
	B61	EP 0 664 122	07/26/95	Europe				
	B62	EP 0 664 123	07/26/95	Europe				
	B63	EP 0 664 124 A1	07/26/95	Europe				
	B64	EP 0 664 125	07/26/95	Europe				
	B65	EP 0 664 198	07/26/95	Europe				
	B66	EP 0 665 015 A2	08/02/95	Europe				
	B67	EP 0 668 075 A2	08/23/95	Europe				
	B68	EP 0 670 162	09/06/95	Europe				
	B69	EP 0 674 903	10/04/95	Europe				
	B70	EP 0 675 121	10/04/95	Europe				
	B71	EP 0 684 259 A1	11/29/95	Europe				
	B72	EP 0 699 673	03/06/96	Europe				
	B73	EP 0 734 721 A2	10/02/96	Europe				
	B74	WO 00/00238	01/06/00	PCT				
	B75	WO 0047197	08/17/00	PCT (with English abstract).				
	B76	WO 85/00107	01/17/85	PCT				
	B77	WO 89/03232 A1	04/20/89	PCT				
	B78	WO 90/07328	07/12/90	PCT				
	B79	WO 90/12597	11/01/90	PCT				
	B80	WO 91/08291	06/13/91	PCT				
	B81	WO 91/15222	10/17/91	PCT				
	B82	WO 91/17789 A1	11/28/91	PCT				
	B83	WO 91/18940 A1	12/12/91	PCT				
	B84	WO 92/00330	01/09/92	PCT				
	B85	WO 92/06068	04/16/92	PCT				
	B86	WO 92/08480	05/29/92	PCT				
	B87	WO 92/11872	07/23/92	PCT				
	B88	WO 92/12717	08/06/92	PCT				
	B89	WO 92/15286	09/17/92	PCT				
	B90	WO 92/19612	11/12/92	PCT				
	B91	WO 93/04191	03/04/93	PCT				
	B92	WO 93/09228	05/13/93	PCT				
	B93	WO 93/09765	05/27/93	PCT				
	B94	WO 93/09800	05/27/93	PCT				
	B95	WO 93/09802	05/27/93	PCT				
	B96	WO 93/10808	06/10/93	PCT				
	B97	WO 93/11757	06/24/93	PCT				
	B98	WO 93/16724	09/02/93	PCT				
	B99	WO 93/19746	10/14/93	PCT				

	B100	WO 93/19769	10/14/93	PCT				
	B101	WO 94/01056	01/20/94	PCT				
	B102	WO 94/02595	02/03/94	PCT				
	B103	WO 94/07529	04/14/94	PCT				
	B104	WO 94/09010	04/28/94	PCT				
	B105	WO 94/09764	05/11/94	PCT				
	B106	WO 94/09812	05/11/94	PCT				
	B107	WO 94/10187	05/11/94	PCT				
	B108	WO 94/16706	08/04/94	PCT				
	B109	WO 94/20098	09/15/94	PCT				
	B110	WO 94/20099	09/15/94	PCT				
	B111	WO 94/20116	09/15/94	PCT				
	B112	WO 94/20117	09/15/94	PCT				
	B113	WO 94/20126	09/15/94	PCT				
	B114	WO 94/20127	09/15/94	PCT				
	B115	WO 94/21308	09/29/94	PCT				
	B116	WO 94/21309	09/29/94	PCT				
	B117	WO 94/23068	10/13/94	PCT				
	B118	WO 94/24961	11/10/94	PCT				
	B119	WO 94/25588	11/10/94	PCT				
	B120	WO 94/26888	10/06/95	PCT				
	B121	WO 95/04544	02/16/95	PCT				
	B122	WO 95/05191	02/23/95	PCT				
	B123	WO 95/10611	04/20/95	PCT				
	B124	WO 95/17095	06/29/95	PCT				
	B125	WO 95/19987	07/27/95	PCT				
	B126	WO 95/30900	11/16/95	PCT				
	B127	WO 96/01102	01/18/96	PCT				
	B128	WO 96/07402	03/14/96	PCT				
	B129	WO 96/15224	05/23/96	PCT				
	B130	WO 96/21442	07/18/96	PCT				
	B131	WO 96/21443	07/18/96	PCT				
	B132	WO 96/24356	08/15/96	PCT				
	B133	WO 96/32907	10/24/96	PCT				
	B134	WO 96/36349	11/21/96	PCT				
	B135	WO 96/40098	12/19/96	PCT				
	B136	WO 97/10011	03/20/97	PCT				
	B137	WO 97/15319	05/01/97	PCT				
	B138	WO 97/22697	06/26/97	PCT				
	B139	WO 97/33552	09/18/97	PCT				
	B140	WO 97/45105	12/04/97	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	"Breast Cancer Prevention Trial Should Resume, ODAC Says", <i>The Breast Cancer Letter</i> , 20, 4-5, (June 17, 1994)
	C02	"Churchill's Medical Dictionary", <i>definition of "cytostatic"</i> , 473, (1989)
	C03	"Glaxo Wellcome Preclinical Data: Preclinical studies conducted with GW 5638, a selective estrogen receptor modulator developed by Glaxo Wellcome, indicate that the compound acts both as an agonist and antagonist at

		estrogen receptor within specific ...", R & D Focus Drug News, (September 8, 1997)
	C04	"Growth Factor Via Gene Therapy Abates Sore Rheumatoid Joints", BioWorld Today: The Daily Biotechnology Newspaper, 9(115), Leff, David N., Editor, 1, (June 17, 1998)
	C05	"Health Report -- The Good News", Time, 23, (Apr. 1, 1996)
	C06	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, p. 399, (1982)
	C07	"ICI United States, Inc., Tamoxifen citrate, Summary For Basis of Approval", (December 30, 1977)
	C08	"Johnson & Johnson receives FDA approval to market Palmaz Balloon-expandable Stent for iliac arteries," Business Wire, Oct. 2, 1991.
	C09	"Micellar and Lyotropic Liquid Crystalline Phases Containing Nonionic Active Substances", In: Lyotropic Liquid Crystals and the Structure of Biomembranes, S. Friberg, (ed.), Advances in Chemistry Series, No. 152, American Chemical Society, 28-42, (1976)
	C10	"Muscle-Binding Gene Sees Two-Track Payoff: Human Therapies, Animal Meat", BioWorld Today: The Daily Biotechnology Newspaper, 8(85), Leff, David N., Editor, 1-3, (May 2, 1997)
	C11	"Nolvadex Tamoxifene Citrate", ICI Pharma, 64033-02, Rev L/07/92
	C12	"Prevention of Coronary Heart Disease", In: Avery's Drug Treatment — Principles and Practice of Clinical Pharmacology and Therapeutics, Speight, T. M., (ed.), Williams and Wilkins, Baltimore, 594-595, (1987)
	C13	"Quantikine – Human TGFbeta1 Immunoassay", Product Brochure, Catalog No. DB100, R&D Systems, Inc., p. 1-19,
	C14	"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16, (Oct. 23, 1995)
	C15	"Tamoxifen therapy found safe for survivors of breast cancer", Fred Hutchinson Cancer Research Center Newsletter, 1(21), (October 1995)
	C16	"Toprol XLTM Tablets", In: Physician's Desk Reference., 658-660, (Probably 1992)
	C17	Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489, (1991)
	C18	AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", Fertility and Sterility, 48, 113-117, (July 1987)
	C19	Akselband, Y., et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts", Transplantation Proceedings, 23, 2833-2836, (1991)
	C20	Alberts, B. et al., "Molecular Biology of the Cell" 2 nd edition 1989, p653
	C21	Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of the Cell, Garland Publishing, London, 571, (1983)
	C22	Alderson, T. 1990.. "New targets for cancer chemotherapy – poly(ADP-ribosylation) processing and polyisoprene metabolism," Biol. Rev. 65:623-641
	C23	Aldridge, D.C., et al., "The Structures of Cytochalasins A and B", J. Chem. Soc., 17, 1667-1676, (1967)
	C24	Alich, A.A., et al., "Comparison of Aspirin and Copper Aspirinate with Respect to Gastric Mucosal Damage in the Rat", Journal of Pharmaceutical Sciences, 72, 1457-1461, (Dec. 1983)
	C25	Alich, A.A., et al., "Gastric Mucosal Damage Due to Aspirin and Copper Aspirinate Assessed by Gastric Mucosal Potential Difference Changes", Journal of Pharmacological and Toxicological Methods, 27, 245-250, (Jul. 1992)
	C26	Alich, A.A., et al., "Response to: 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 73, Open Forum, 1876-1877, (Dec. 1984)
	C27	Allen, K.E., et al., "Evidence For The Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity Relationships", Br.J. Pharmac., 71, 83-91, (1980)
	C28	Allen, R.E. & Boxhor, L.K. "Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta," J Cell. Physiol. 133:567-572.(1987)
	C29	Allgemeine und spezielle Pharmakologie und Toxikologie, by W. Forth et al. 1984, pages 524-531 and 627-633
	C30	Alvarado, et al. "Evaluation of Polymer-Coated Balloon Expandable Stents in Bile Ducts," Radiology 165 (suppl.):33 1 (1987)
	C31	Anderson et al., "Restenosis after coronary angioplasty," J. Interv. Cardiol., 6(3)187-202 (1993)
	C32	Anderson, et al., "Effects of Acetate Dialysate on Transforming Growth Factor β_1 , Interleukin, and β_2 -Microglobulin Plasma Levels," Kidney International, Vol. 40, pp. 1110-1117 (1991)
	C33	Ando et al., "Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury", Eur. J. Pharmacol., 438:207-14 (2004)
	C34	Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", Int. J. Cancer, 60, 365-368, (1995)
	C35	Arao, Y., et al., "A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression", Biochem. J., 313, 269-274, (1996)
	C36	Askelband et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts", Transplantation Proceedings, 23 2833-2836 (1991)
	C37	Assoian and Sporn, "Type beta Transforming Growth Factor in Human Platelets: Release During Platelet Degranulation and Action on Vascular Smooth Muscle Cells," The Journal of Cell Biology, Vol. 102, pp. 1217-

		1223 (1986)
	C38	Assoian et al., "Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization", J. Biol. Chem. 258:7155-7160 (1983)
	C39	Assoian, R.K., et al., "Cellular Transformation by Coordinated Action of Three Peptide Growth Factors from Human Platelets", Nature, 309, 804-806, (June 28, 1984)
	C40	Assoian, R.K. & Spore, M.B. "Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells," J. Cell Biol. 102:1217-1233.(1986)
	C41	Babaev, et al., "Heterogeneity of smooth muscle cells in atheromatous plaques of human aorta," Am J. Pathol. 136:1031- 1042. (1990)
	C42	Bagdade, et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition," J. of Clinical Endocrinology and Metabolism, Vol. 70, No. 4, pp. 1132-35 (1990)
	C43	Bailey <i>et al.</i> , "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after stent placement." Circulation 82:III-541 (1990)
	C44	Baim, D.S., et al., "Nonatherosclerotic Coronary Heart Disease", In: The Heart: Arteries and Veins, Sixth Edition, Logue, R.B., et al., (eds.), McGraw-Hill Book Company, New York, 1016-1025, (1986)
	C45	Bang, H.O., et al., "The Composition of the Eskimo Food in North Western Greenland", Am. J. Clin. Nutr., 33, 2657-2661, (1980)
	C46	Baqual, J.G., et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the Pharmacological Activities of Cu(II)sub2(3,5-Diisopropylsalicylate)sub4., J. Inorganic Biochem., 60, 133-148, (1995)
	C47	Baral, E., et al., "Modulation of Lymphokine-Activated Killer Cell-Mediated Cytotoxicity By Estradiol and Tamoxifen", Int. J. Cancer, 66, 214-218, (1996)
	C48	Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 1991, pp. 1259-1274
	C49	Barnard, et al., "Regulation of intestinal epithelial cell growth by transforming growth factor-beta." Proc. Natl Acad. Sci. USA 86:1518-1582.(1989)
	C50	Bartoli et al. "In vitro and in vivo Antitumoral Activity of Free, and Encapsulated taxol". J. Microencapsulation, 7 (2):191-197, 1990
	C51	Basel, C. T., "The Antibiotic Complex of the Verrucarins and Roridins," Fortschr. Chem. Org. Naturst., 31:65 117 (1974)
	C52	Bassing et al., "FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes", Cell Growth Differ., 9(3):223-8 (1998)
	C53	Battegay et al., "TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop", Cell, 63:515-524 (1990)
	C54	Baxter Healthcare Corp. Duroflo Biocompatible Treatment
	C55	Beck, L., et al., "Vascular Development: Cellular and Molecular Regulation", The FASEB Journal, 11, 365-373, (1997)
	C56	Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces,, J. Biomed. Materials Res. v26 1992, p. 779-790
	C57	Bernhardt et al., "Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation", J. Cardiovasc. Pharmacol., 21(6):973-6 (1993)
	C58	Bertelli, et al., "Adjuvant Tamoxifen in Primary Breast Cancer: Influence on Plasma Lipids and Antithrombin III Levels," Breast Cancer Res. and Treatment, Vol. 12, pp. 307-310 (1988)
	C59	Berven, L.A., et al., "Cellular Function of p70S6K: A Role in Regulating Cell Motility", Immunology and Cell Biology, 78, 447-451, (2000)
	C60	Billmeyer, F., Textbook of Polymer Science (2d ed.) John Wiley & Sons, Inc. (1971)
	C61	Binmoeller, <i>et al.</i> , "Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study" Endoscopy 1992; 24:416-20.
	C62	Bittiner, S.B., et al., "A Double-Blind, Randomised, Placebo-Controlled Trial of Fish Oil in Psoriasis", The Lancet, 1, 378-380, (Feb. 20, 1988)
	C63	Bjorkerud, "Effects of transforming growth factor-beta1 on human arterial smooth muscle cells in vitro", Arterioscler. Thromb., 11(4):892-902 (1991)
	C64	Block, P.C. "Coronary-artery stents and other endoluminal devices," New Engl.J.Med. 1991; 324-52-3
	C65	Bluming, "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Cancer", Seminars in Oncology, 20, 662-674, (December 1993)
	C66	Bohmova et al., "Effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat", Transplant Proc., 34(8):3051-3052 (2002)
	C67	Border, W.A., et al., "Targeting TGF-Beta for Treatment of Disease", Nature Medicine, 1(10), 1000-1001, (October 1995)
	C68	Boscoboinik et al., "Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity", Arch. Biochem. Biophys., 286(1):264-9 (1991)

C69	Boyle, "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture", Curr. Vasc. Pharmacol., 3(1):63-8 (2005)
C70	Brand, C., et al., "Transforming Growth Factor Betal Decreases Cholesterol Supply to Mitochondria via Repression of Steroidogenic Acute Regulatory Protein Expression", The Journal of Biochemistry, 273(11), 6410-6416, (1998)
C71	Braun-Dullaues et al., "Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin", Arterioscler Thromb Vasc Biol. 21(7):1152-58 (2001)
C72	Brem et al., "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumours." European Journal of Pharmaceuticals and Biopharmaceutics, 1993, Vol, 39, No. 1, pp 2-7
C73	Brody, J.E., "Study Finds New Estrogen Offers Benefit Without Risk", The New York Times, A32, (December 4, 1997)
C74	Bruengger, et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs," J. Urol. Vol. 130, No. 6, pp. 1208-10 (1983)
C75	Bruning, et al., "Tamoxifen, Serum Lipoproteins and Cardiovascular Risk", Br. J. Cancer, 58, 497-499 (1988)
C76	Burr, M.L., et al., "Effects of Changes in Fat, Fish and fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trial (DART)", The Lancet, 757-761, (Sep. 30, 1989)
C77	Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6, (June 6, 1997)
C78	Butta, et al., "Induction of Transforming Growth Factor β_1 in Human Breast Cancer in vivo Following Tamoxifen Treatment," Cancer Res. Vol. 52, pp. 4261-64 (1992)
C79	C. Chamsangavej et al., A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation, Houston Medical Journal 1987;2:41-51 ..
C80	C. T. Dotter, "Transluminally Placed Coil Spring Endarterial Tube Grafts Long Term Patency in Canine Popliteal Arteries," Investigative Radiology 1969;4:329- 332.
C81	Calver et al. "Intracoronary Multi-link stents: experience in 218 patients using aspirin alone," Heart 1998;80:499-504
C82	Casscells, W., et al., "Elimination of Smooth Muscle Cells in Experimental Restenosis: Targeting of Fibroblast Growth Factor Receptors", Proc. Natl. Acad. Sci. USA, 89, 7159-7163 (1992)
C83	Castellot et al., "Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth", J. Cell Biol., 90:372-379 (1981)
C84	Castellot et al., "Effect of heparin on vascular smooth muscle cells. I. Cell metabolism", J. Cell. Physiol., 124:21-28 (1985)
C85	Castellot et al., Heparin selectively inhibits a protein kinase c-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells, J Cell Biol., 109:3147-3155 (1989)
C86	Chamberlain, 'Transforming growth factor-beta: a promising target for anti-stenosis therapy', Cardiovasc. Drug Rev., 19(4):329-344 (2001)
C87	Chamley-Campbell and Campbell, "What controls smooth muscle phenotype?", Atherosclerosis, 40:347-357 (1981)
C88	Chamsangavej et al., "Endovascular Stent for Vena Caval Stenosis: Laboratory Experiment and Potential Clinical Applications," Radiology 1985 Nov;157(P):66 Abs. 129.
C89	Chander, et al., "Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, New Analogues of the Antiestrogen Tamoxifen for the Treatment of Breast Cancer," Cancer Research, Vol. 51, pp. 5851-5858 (1991)
C90	Chandrasekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor Beta mRNA and Protein Expression", Journal of Autoimmunity, 8, 381-393, (1995)
C91	Chandy, T., et al., "Chitosan Matrix for Oral Sustained Delivery of Ampicillin", Biomaterials, 14, 939-944, (1993)
C92	Chao, et al., "Altered Cytokine Release in Peripheral Blood Mononuclear Cell Cultures from Patients with the Chronic Fatigue Syndrome," Cytokine, Vol. 3, No. 4, pp. 292-298 (1991)
C93	Charles Dotter et al., "Transluminally Treatment of Arteriosclerotic Obstruction Description of a New Technique and a Preliminary Report of its Application," Circulation 1964;30:654-669
C94	Charlier, C., et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 cells", Biochemical Pharmacology, 49(3), 351-358, (January 1995)
C95	Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol. Reprod., 23, 751-756, (1994)
C96	Charnsangavej, et al., "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology 1986 Nov;161:295.
C97	Cheitlin, M.D., et al., "Myocardial Infarction without Atherosclerosis", JAMA, 231, 951-959, (1975)
C98	Chen et al., "Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells", Proc. Natl. Acad. Sci., 84:5287-5291 (1987)
C99	Clark, D.A., et al., "Coronary Artery Spasm: Medical Management, Surgical Denegation, and Autotransplantation", The Journal of Thoracic and Cardiovascular Surgery, 73, 332-339, (1977)
C100	Clarke, S.C., et al., "Tolerance and Responses To Tamoxifen and Toremifene in Male Patients with Coronary Artery Disease.", Abstract for ACC Meeting, March 1999
C101	Clinton, S.K., "Induction in vivo of Interleukin-1 (IL-1) Gene Expression in Rabbit Aortic Tissue", Abstracts of the 61st Scientific Sessions, II-65

	C102	Clowes and Kamowsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", <i>Nature</i> , 265:625-626 (1977)
	C103	Clowes et al., "Heparin and cilazapril together inhibit injury-induced intimal hyperplasia", <i>Hypertension</i> , 18:II-65-II-69 (1991)
	C104	Colletta, A.A. et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", <i>Br. J. Cancer</i> , 62, 405-409, (1990)
	C105	Columbo et al., "A Novel Strategy for Stent Deployment in the Treatment of Acute or Threatened Closure Complicating Balloon Coronary Angioplasty," <i>JACC</i> 1993 Dec;22(7):1887-91,
	C106	Comezoglu, F.T. et al., "Serum Stability and Cytotoxicity of the Macrocyclic Trichothecenes Roridin A, Verrucaric Acid and Their Monoclonal Antibody Conjugates", <i>Proceedings of the American Association for Cancer Research</i> , 31, Abstract No. 1723, p. 291, (Mar., 1990)
	C107	Coomber and Gotlieb "In vitro endothelial wound repair. Interaction of cell migration and proliferation". <i>Atherosclerosis</i> , 10 (2):215-222, 1990
	C108	Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", <i>Cancer Research</i> , 55, 1070-1074, (Mar. 1, 1995)
	C109	Corcos, et al., "Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty", <i>Am. Heart J.</i> , 109(5):926-931 (1985)
	C110	Cox et al., "Effects of local delivery of heparin and methotrexate on neointimal proliferation in stented porcine coronary arteries". <i>Coronary Artery Disease</i> , 3:237-248, 1992
	C111	Cox et al., "Local Delivery of Heparin and methotrexate fails to inhibit in vivo smooth muscle cell proliferation". <i>Circulation Suppl.</i> 84(4):II-71, #0284, 1991
	C112	Csernok, E., et al., "Transforming Growth Factor-beta (TGF-beta) Expression and Interaction with Proteinase 3 (PR3) in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis", <i>Clin. Exp. Immunol.</i> , 105, 104-111, (1996)
	C113	Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", <i>Mutation Research</i> , 349, 85-94, (1996)
	C114	Dangas, G., et al., "Management of Restenosis after Coronary Intervention", <i>American Heart Journal</i> , 132, 428-436, (1996)
	C115	Danielpour, David, "Improved Sandwich Enzyme-Linked Immunosorbent Assays for Transforming Growth Factor," <i>Journal of Immunological Methods</i> , Vol. 158, pp. 17-25 (1993)
	C116	Danielpour, et al., "Evidence for Differential Regulation of TGFβ1 and TGFβ2 Expression in Vivo by Sandwich Enzyme-linked Immunosorbent Assays," <i>Annals New York Academy of Sciences</i> , pp. 300-302
	C117	Danielpour, et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF-1 and TGF-2) Secreted by Cells in Culture," <i>Journal of Cellular Physiology</i> , Vol. 138, pp. 79-86 (1989)
	C118	Dasch, et al., "Capture Immunoassays Specific for TGF1 and TGF2: Use in Pharmacokinetic Studies," <i>Annals New York Academy of Sciences</i> , pp. 303-305
	C119	Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", <i>Carcinogenesis</i> , 16, 539-545, (1995)
	C120	deAlvarez, L.R., et al., "Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylato)-Copper(II) Complex", <i>Biochemical and Biophysical Research Communications</i> , 69, 687-694, (1976)
	C121	Dehmer, G.J., et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", <i>N. Engl. J. Med.</i> , 319, 733-740, (1988)
	C122	Del Vecchio et al., "Inhibition of human scleral fibroblast proliferation with heparin, Invest". <i>Ophthalmol. Vis. Sci.</i> , 29:1272-1276 (1988)
	C123	Delmas, P.D., "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women", <i>The New England Journal of Medicine</i> , 337(23), (1997)
	C124	DiGiacomo, R.A., et al., "Fish-Oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-Blind, Controlled, Prospective Study", <i>Am. J. Med.</i> , 86, 158-164, (Feb. 1989)
	C125	DiLuccio, R.C., et al., "Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers", <i>Journal of Pharmaceutical Sciences</i> , 83, 104-106, (January 1994)
	C126	Dimond, Patricia F., Ph.D., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes," <i>Genetic Engineering News</i> , pp. 7 & 19 (1993)
	C127	Donnelly, J., et al., "Protective Efficacy of Intramuscular Immunization with Naked DNA; DNA Vaccines: A New Era in Vaccinology, Margaret A. Liu et al., eds.", <i>Annals of the New York Academy of Sciences</i> , 772, 40-44, (1995)
	C128	Dotter, "Intraventional Radiology - Review of an Emerging Field," <i>Seminars In Roentgenology</i> 1982;16(1):7-8,
	C129	Dove, C.R., et al., "Effect of Vitamin E and Copper on the Vitamin E Status and Performance of Growing Pigs", <i>J. Anim. Sci.</i> , 69, 2516-2523, (1991)
	C130	Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: <i>The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation</i> , The Gloucester Hotel, London, 7 p., (Mar. 13-14, 1995)
	C131	Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", <i>Carcinogenesis</i> , 16, 2733-2741, (1995)
	C132	Draper, M.W., et al., "Antiestrogenic Properties of Raloxifene", <i>Pharmacology</i> , 50, 209-217, (April 1995)
	C133	Dyerberg, J., "Platelet-Vessel Wall Interaction: Influence of Diet", <i>Phil. Trans. R. Soc. Lond.</i> , B 294, 372-381,

		(1981)
	C134	Dyerberg, J., et al., "The Effect of Arachidonic- and Eicosapentaenoic Acid on the Synthesis of Prostacyclin-like Material in Human Umbilical Vasculature", <i>Artery</i> , 8, 12-17, (1980)
	C135	Ebner, et al., "Cloning of a Type I TGF- β Receptor and Its Effect on TGF- β Binding to the Type II Receptor," <i>Science</i> , Vol. 260, pp. 1344-48 (1993)
	C136	Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury", <i>Proc. Natl. Acad. Sci. USA</i> , 87, 3773-3777, (May, 1990)
	C137	Ellis et al., "Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty", <i>Am. Heart J.</i> , 117(4):777-782 (1989)
	C138	Ellis, S.G., et al., "In-Hospital Cost of Percutaneous Coronary Revascularization: Critical Determinants and Implications", <i>Circulation</i> , 92, 741-747, (1995)
	C139	Endres, S., et al., "The Effect of Dietary Supplementation with n-3 polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells", <i>N. Engl. J. Med.</i> , 320, 265-271, (1989)
	C140	Esnouf, M.P., et al., "The Inhibition of the Vitamin K-Dependent Carboxylation of Glutamyl Residues in Prothombin by Some Copper Complexes", <i>FEBS Letters</i> , 107, 146-150, (1979)
	C141	Espinosa, E., et al., "17-Estradiol and Smooth Muscle Cell Proliferation in Aortic Cells of Male and Female Rats", <i>Biochemical and Biophysical Research Communication</i> , 221, 8-14, (1996)
	C142	Ettenson and Gotlieb "Centrosomes, Microtubules, and Microfilaments in the Reendothelialization and Remodeling of Double-Sided In Vitro Wounds". <i>Laboratory Investigation</i> , Vol. 68, No. 6, pp. 722-733, 1992, United States and Canadian Academy of Pathology, Inc.
	C143	Evans, G.L., et al., "Tissue-Selective Actions of Estrogen Analogs", <i>Bone</i> , 17, 181S-190S, (October 1995)
	C144	Farhat, et al., "In Vitro Effect of Oestradiol on Thymidine Uptake in Pulmonary Vascular Smooth Muscle Cell: Role of the Endothelium," <i>Br. J. Pharmacol.</i> Vol. 107, pp. 679-683 (1992)
	C145	Faxon et al., "Enozaprain, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomized trial", <i>JACC</i> 19:258A, Abstract 783-3 (1992)
	C146	Ferrari, R.P., et al., "Changes of Serum Iron Transferrin and Copper Ceruloplasmin in Rats Given Cu(II) sub2 (Acetylsalicylate) sub4 During Acute Inflammation", <i>Anticancer Res.</i> , 9, 771-774, (1989)
	C147	Fett-Neto, A.G., et al., "Effect of White Light on Taxol and Baccatin III Accumulation in Cell Cultures of <i>Taxus Cuspidata</i> Sieb and Zucc.", <i>J. Plant Physiol.</i> , 146, 584-590, (1995)
	C148	Fischer, et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis Experimental and Molecular Pathology", <i>Exp. Mol. Pathol.</i> , 43 288-296 (1985)
	C149	Fisher, M., et al., "Dietary n-3 Fatty Acid Supplementation Reduces Superoxide Production and Chemiluminescence in a Monocyte-Enriched Preparation of Leukocytes", <i>Am. J. Clin. Nutr.</i> , 51, 804-808, (1990)
	C150	Flanders, K.C., et al., "Altered Expression of Transforming Growth Factor-B in Alzheimer's Disease", <i>Neurology</i> , 45, 1561-1569, (August 1995)
	C151	Flanders, K.C., et al., "Transforming Growth Factor-B1: Histochemical Localization With Antibodies to Different Epitopes", <i>Journal of Cell Biology</i> , 108, 653-660, (Feb. 1989)
	C152	Foekens, J.A., et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer", <i>Journal of the National Cancer Institute</i> , 87(10), 751-756, (May 1995)
	C153	Forney-Prescott et al., "Angiotensin-converting enzyme inhibito' versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury", <i>Am J Pathol</i> , 139:1291-1296 (1991)
	C154	Fox and DiCorleto, "Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein", <i>Science</i> , 241 (4864):453-456 (1988)
	C155	Frautschy, S.A., et al., "Rodent Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid Deposits", <i>Neurobiology of Aging</i> , 17, 311-321, (1996)
	C156	Frazier-Jessen, et al., "Estrogen Modulation of JE/Monocyte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages", <i>J. Immunol.</i> , 1828-1845
	C157	Frye, L.L., et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", <i>Journal of Lipid Research</i> , 35, 11333-1344, (1994)
	C158	Fukaura, H., et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor- B1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", <i>J. Clin. Invest.</i> , 98, 70-77, (1996)
	C159	Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kyoto Rats", <i>Clin. Exp. Pharmacol. Physiol. Supply.</i> , 1, S120, 1995
	C160	Furr, B.J., et al., " The Pharmacology and Clinical Uses of Tamoxifen", <i>Pharmac. Ther.</i> , 25, 127-205, (1984)
	C161	Gebhardt, R., et al., "Differential Inhibitory Effects of Garlic-Derived Organosulfur Compounds on Cholesterol Biosynthesis in Primary Rat Hepatocyte Cultures", <i>Lipids</i> , 31, 1269-1276, (1996)
	C162	Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis by Allicin and Ajoene in Rat Hepatocytes and HepG2 Cells", <i>Biochimica et Biophysica Acta</i> , 1213, 57-62, (1994)
	C163	Giachelli, et al., "Osteopontin is Elevated During Neointima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", <i>J. Clin. Invest.</i> , 92, 1686-1696, (Oct. 1993)
	C164	Gibson, D.M., et al., "Initiation and Growth of Cell Lines of <i>Taxus Brevifolia</i> (Pacific Yew)", <i>Plant Cell Reports</i> ,

		12, 479-482, (1993)
	C165	Goodnight, S.H., "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", Arch. Pathol. Lab. Med., 117, 102-106, (January, 1993)
	C166	Gradishar, W.J., et al., "Clinical Potential of New Antiestrogens", Journal of Clinical Oncology, 15, 840-852, (1997)
	C167	Grainger and Metcalfe, "Transforming growth factor- β and cardiovascular protection, draft"(NeoRx 019151-019213)
	C168	Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995)
	C169	Grainger and Mosedale, "TGF- β and the cardiovascular system, TGF- β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190).
	C170	Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000)
	C171	Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex," DJG 003915-003920.
	C172	Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscle cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998)
	C173	Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213)
	C174	Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995)
	C175	Grainger, D.J., et al., "Release and Activation of Platelet Latent TFG-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937, (1995)
	C176	Grainger, D.J., et al., "Tamoxifen Elevates Transforming Growth Factor-beta and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", Nature Medicine, 1, 1067-1073, (Oct., 1995)
	C177	Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", Nature Medicine, 2, 381-385, (Apr., 1996)
	C178	Grainger, D.J., et al., "Transforming Growth Factor-beta and Cardiovascular Protection", In: The Endothelium in Clinical Practice, Rubanyi, G.M., et al., (eds.), Marcel Dekker, Inc., New York, 203-243, (1997)
	C179	Grainger, D.J., et al., "Transforming Growth Factor-beta is Sequestered into an Inactive Pool by Lipoproteins", Journal of Lipid Research, 38, 117-125, (1997)
	C180	Grainger, D.J., University of Cambridge Ph.D. Thesis, Control of the proliferation and differentiation of vascular smooth muscle cells, DJG 005911-006102 (1992) and all references therein
	C181	Gravlee, G.P. MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, April 1994, pp. 213-222
	C182	Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", Transplantation, 55 1409-1418 (1993)
	C183	Gregory et al., "Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury", Transplant. Proc., 25:120-21 (1993)
	C184	Grese, T.A., et al., "Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modification to the 2-Arylbenzothiophene Core of Raloxifene", J. Med. Chem., 40, 146-167, (1997)
	C185	Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal Postmenopausal Women", J. Clinical Endocrinology and Metabolism, 80, 3191-3195, (1995)
	C186	Grigg, L.E., et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", JACC, 13, 655-672, (1989)
	C187	Gruntzig, et al., "Nonoperative Dilatation of Coronary-Artery Stenosis," New England J. Med.. 1979 Jul 12;301(2):61-68.
	C188	Guba et al., "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor", Nat. Med., 8(2):128-35 (2002)
	C189	Guetta, V., et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", The American Journal of Cardiology, 76, 1072-1073, (November 15, 1995)
	C190	Gulino, A., et al., "Heterogeneity of Binding Sites for Tamoxifen and Tamoxifen Derivatives in Estrogen Target and Nontarget Fetal Organs of Guinea Pig, Cancer Research 42, 1913-1921, (May 1982)
	C191	Guyton et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and noncoagulant heparin", Circ. Res., 46(5):625-634 (1980)
	C192	Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Delta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", Journal of Clinical Oncology, 13, 2900-2905, (1995)
	C193	Gylling, H., et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", Atherosclerosis, 96, 245-247, (1992)
	C194	Hafzi et al., "Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling", Vascu. Pharmacol., 41:167-76 (2004)
	C195	Hahn, L., et al., "The Influence of Acetylsalicylic Acid and Paracetamol on Menstrual Blood Loss in Woman With and Without an Intrauterine Contraceptive Device", Am. J. Obstet. Gynecol., 135, 393-396, (1979)
	C196	Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-borane-carboxylato)-bis (trimethylamine-carboxyborane) -dicopper (II) in Rodents and Its Effect on Lipid Metabolism", J. Pharmaceut.

		Sci., 73, 973-977, (1984)
	C197	Hanson, <i>et al.</i> , "In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis," J. Lab. Clin. Med. 95:289-304; 1980
	C198	Hanson, <i>et al.</i> , "Testing of Blood – Materials Interactions," Biomaterials Science (B.D. Ratner, Ed.), Academic Press, 222-238 (1996).
	C199	Hanson, S., "Device Thrombosis and Thromboembolism," Cardiovasc Pathol. 2(3) (Suppl.): 157S-165S (July-Sept. 1993)
	C200	Harpel, <i>et al.</i> , "Plasmin Catalyzes Binding of Lipoprotein (α) to Immobilized Fibrinogen and Fibrin," Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 3847-3851 (1989)
	C201	Harrison, D.C., "Nonatherosclerotic Coronary Artery Disease", In.: Atherosclerosis and Coronary Artery Disease, V. Fuster, <i>et al.</i> , (eds.), Lippencott-Raven Publishers, pp. 757-772, (1996)
	C202	Hayden, L.J., "Inhibitors of Gastric Lesion in the Rat", J. Pharm. Pharmac., 30, 244-246, (1978)
	C203	Hayes, D.F., <i>et al.</i> , "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566, (Oct. 1995)
	C204	Hehrlein, C., <i>et al.</i> , "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", Circulation, 93, 641-645, (1996)
	C205	Heldin, <i>et al.</i> , "Demonstration of an Antibody Against Platelet-derived Growth Factor," Experimental Cell Research, Vol. 136, pp. 255-261 (1981)
	C206	Hermann and Hirshfeld, Jr., "Clinical Use of the Palmaz-Schatz Intracoronary Stent," Futura Publishing Co. (1993).
	C207	Hermans <i>et al.</i> , "Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet"" American Heart Journal, 122 (1) Part, 1, 171-187, 1991
	C208	Hirata <i>et al.</i> , "Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate". Arthritis and Rheumatism, 32(9): 1065-1073, 1989
	C209	Hoffman, A., "Modification of Material Surfaces to Affect How They Interact with Blood, Blood in Contact with Natural and Artificial Surfaces," Leonard, E. <i>et al.</i> , (eds), Annals of the New York Academy of Sciences, 516:96-100 (1987)
	C210	Holmes, <i>et al.</i> , "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis", Circulation, 109:634-640 (2004)
	C211	Hoover, <i>et al.</i> , "Inhibition of rat arterial smooth muscle cell proliferation by heparin:II. In vitro studies", Circ. Res., 47(4):578-83 (1980)
	C212	Hopfenberg, H., "Transport Through Polymers, 7 Encyclopedia of Materials Science and Engineering," (Michael B. Bever, (ed.); The MIT Press, 5141-5145 (1986)
	C213	Howell, A., <i>et al.</i> , "New Endocrine Therapies for Breast Cancer", European Journal of Cancer, 32A, 576-588, (1996)
	C214	Hsu, Li-Chien "Principles of Heparin-Coating Techniques", Perfusion 6: 209-219 (1991)
	C215	Huang, <i>et al.</i> , "Rapamycins: mechanism of action and cellular resistance." Cancer Biol. Ther., 2(3):222-32 (2003)
	C216	Huang, S.S., <i>et al.</i> , "Transforming Growth Factor Beta peptide Antagonists and Their Conversion to Partial Agonists", The Journal of Biological Chemistry, 272(43), 27155-57159, 1997
	C217	Hughes, D.E., <i>et al.</i> , "Estrogen Promotes Apoptosis of Murine Osteoclasts Mediated by TFG-beta", Nature Medicine, 2, 1132-1136, (1996)
	C218	Hwang <i>et al.</i> , "Effects of Platelet-Contained Growth Factors (PDGF, EGF, IGF-1 and TGF-B) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture." Exp. Cell Res., 200, 358-360 (1992)
	C219	Ishihara, <i>et al.</i> , "Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties," Biomaterials, 1995 16(11): 873-879
	C220	Jacinto and Hall, "Tor signalling in bugs, brain and brawn", Nature Rev. Mol. Cell Biol., 4:117-126 (2003)
	C221	Jampel <i>et al.</i> , "In vitro release of hydrophobic drugs from polyanhydride disks". Ophthal Surg, 23 (11):676-680, 1991
	C222	Jeffrey A. Hubbell, Ph.D., "Pharmacologic Modification of Materials" Cardiovasc Pathol Vol2 No.3 (Suppl.) July-Sept. 199, 1215-1275
	C223	Jeng, <i>et al.</i> , "Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells", Mol. Cell Endocrinol., 92:115-123 (1993)
	C224	Johnston, S.R., <i>et al.</i> , "Changes in Estrogen Receptor, Progesterone Receptor, and ps2 Expression in Tamoxifen-resistant Human Breast Cancer", Cancer Research, 55, 3331-3338, (August 1995)
	C225	Jones, R.H., <i>et al.</i> , "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens beta subL Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", Exp. Eye Res., 57, 783-790, (1993)
	C226	Jordan, A. <i>et al.</i> , "Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle", Medicinal Research Reviews, 18, 259-296, (1998)
	C227	Jordan, V. Craig, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trials," Hormones, Cell Biol. and Cancer: Perspectives and Potentials, pp. 105-123 (1988)
	C228	Jordan, V.C., <i>et al.</i> , "A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment", Annals New York Academy of Science, 761, 138-147, (1995)

	C229	Jordan, V.C., et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro", <i>Molecular Pharmacology</i> , 26, 272-278, (1984)
	C230	Jordan, V.C., et al., "Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer", <i>Annu. Rev. Pharmacol. Toxicol.</i> , 35, 195-211, (1995)
	C231	Joswig, B.C., et al., "Transmural Myocardial Infarction in the Absence of Coronary Arterial Luminal Narrowing in a Young Man with Single Coronary Arterial Anomaly", <i>Catheterization and Cardiovascular Diagnosis</i> , 4, 297-304, (1978)
	C232	Kanzaki, et al., "In vivo effect of TGF-beta1: enhanced intimal thickening by administration of TGF-beta1 in rabbit arteries injured with a balloon catheter", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 15(11):1951-57 (1995)
	C233	Kardami et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", <i>Dev. Biol.</i> , 126:19-28 (1988)
	C234	Kariya et al., "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells". <i>Atherosclerosis</i> , 80:143-147 (1989)
	C235	Kaski, J.C., et al., "Local Coronary Supersensitivity to Diverse Vasoconstrictive Stimuli in Patients with Variant Angina", <i>Circulation</i> , 74, 1255-1265, (1996)
	C236	Kastrati et al., "Restenosis after coronary placement of various stent types," <i>Am. J. Cardiol.</i> , 87:34-49 (2001)
	C237	Ke, H.Z., et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model", <i>Bone</i> , 20, 31-39, (1997)
	C238	Keen, C.L., et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: <i>Biology of Copper Complexes</i> , Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153, (1987)
	C239	Kellen, J.A., "Tamaoxifen Beyond the Antiestrogen", <i>Birkhuser</i> , 392 pages, (1996)
	C240	Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", <i>In Vivo</i> , 10, 511-514, (1996)
	C241	Kemp, P.R., et al., "ID -- A Dominant Negative Regulator of Skeletal Muscle Differentiation -- is Not Involved in Maturation or Differentiation of Vascular Smooth Muscle Cells", <i>FEBS Letters</i> , 368, 81-86, (1995)
	C242	Kim, et al., "Suppression of Vascular Transforming Growth Factor-B1 and Extracellular Matrix Gene Expressions by Cilazapril and Nifedipine in Hypertensive Rats", <i>Clin. Exp. Pharmacol. Physiol. Suppl.</i> , 1, S355, (1995)
	C243	Kim, J. et al., "Production of Taxol and Related Taxanes in <i>Taxus brevifolia</i> Cell Cultures: Effect of Sugar", <i>Biotechnology Letters</i> , 17, 101-106, (Jan., 1995)
	C244	Kirschenlohr, H.L., et al., "Cultures of Proliferating Vascular Smooth Muscle Cells from Adult Human Aorta", In: <i>Human Cell Culture</i> , Jones, G.E., (ED.), Humana Press, Inc., 24 p. (1996)
	C245	Klebe et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", <i>Cell Motil. Cytoskel.</i> , 6:273-281 (1986)
	C246	Klein, H.O. et al., "Experimental Investigations on a Sequential Combination Chemotherapy Protocol" <i>J. Cancer Res. Clin. Oncol</i> vol 96 no.2 Jan, 1980 p 65-78
	C247	Kleinman, N.S., et al., "Prinzmetal's Angina during 5-Fluorouracil Chemotherapy", <i>The American Journal of Medicine</i> , 82, 566-568, (1987)
	C248	Knabbe, C., et al., "Evidence That Transforming Growth Factor beta is a Hormonally Regulated Negative Growth Factor in Human Breast Cancer Cells" <i>Cell</i> , 48 417-428
	C249	Knabbe, C., et al., "Induction of Transforming Growth Factor-B by the Antiestrogens Droloxifene, Tamaoxifen, and Toremifene in MCF-7 Cells", <i>Am. J. Clin. Oncol.</i> 14, S15-S20, (1991)
	C250	Koff, et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cyclin E-Dependent Kinase by TGF-β", <i>Science</i> , Vol. 260, pp. 536-538 (1993)
	C251	Kopp, A., et al., "Transforming Growth Factor Beta2 (TGF-Beta2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", <i>Cancer Research</i> , 55, 4512-4515, (Oct. 15, 1995)
	C252	Kost, J. Langer R, "Controlled Release of Bioactive Agents," <i>Trends in Biotechnology</i> , Vol. 2, No. 2, 1984, pp. 47-51
	C253	Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. I. Effect on Spermatozoa", <i>Fertility and Sterility</i> , 61, 911-914, (May 1994)
	C254	Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Migration Factor and TGF-beta", <i>Circulation</i> , 84, Abstract No. 1829, II-459, (1991)
	C255	Kremer, J.M., et al., "Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis", <i>Annals of Internal Medicine</i> , 106, 497-502, (1987)
	C256	Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", <i>J. Med. Chem.</i> , 39, 2877-2886, (1996)
	C257	Kuzana, S., et al., "Effects of Some Anti-Rheumatic Agents on Copper-Catalyzed Thermal Aggregation of Gamma Globulin", <i>Agents and Actions</i> , 9 375-380, (1979)
	C258	L C.. Palmaz et. al., Expandable Intraluminal Graft: A Preliminary Study, <i>Radiology</i> 1985;1:73-77.
	C259	Laird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting Stent", <i>Circulation</i> , 93, 529-536, (1996)
	C260	Lambert et al., "A new method for arterial drug delivery via removable stent". <i>JACC</i> , 21(2):483A, #834-2, 1992
	C261	Lange, R.A., et al., "Cocaine-Induced Coronary-Artery Vasoconstriction", <i>The New England Journal of Medicine</i> ,

		321, 1557-1562, (1989)
	C262	Lange, R.L., et al., "Nonatheromatous Ischemic Heart Disease following Withdrawal from Chronic Industrial Nitroglycerin Exposure", <i>Circulation</i> , 46, 666-678, (1972)
	C263	Langer, R. et al., "Polymeric Delivery Systems for Macromolecules-Approaches for Studying In Vivo Release Kinetics and Designing Constant Rate Systems", in: <i>Biological Activities of Polymers</i> , Carraher, Jr. and Gebelein (eds), American Chemical Society Symposium Series 186, pp. 95-105 (1982)
	C264	Langer, R. et al., "Polymers for the Sustained Release of Proteins and Other Macromolecules", <i>Nature</i> 263:797-799 (1976)
	C265	Langer, R., "Polymeric Delivery Systems for Controlled Drug Release", <i>Chem. Eng. Communi.</i> 6:1-48 (1980)
	C266	Law et al., "Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells", <i>Mol. Cell. Biol.</i> , 22:8184-8198 (2002)
	C267	Lawn, R.M., et al., "Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice", <i>The Journal of Biological Chemistry</i> , 271, 31367-31371, (1996)
	C268	Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", <i>Biochem. Cell Biol.</i> , 68, 210-217, (1990)
	C269	LC. Palmaz et al., Expandable Intraluminal Vascular Graft: A Feasibility Study, <i>Surgery</i> 1986 Feb; 199(2): 199-205.
	C270	Lefer, Allen M., "Role of Transforming Growth Factor β in Cardioprotection of the Ischemic-Reperfused Myocardium," <i>Growth Factors and the Cardiovascular System</i> , Chapter 14 (Cummins, P. ed.), Kluwer Academic Publishers, pp. 249-260 (1993)
	C271	Lefer, et al., "Mechanism of the Cardioprotective Effect of Transforming Growth Factor β_1 , in Feline Myocardial Ischemia and Reperfusion," <i>PNAS (USA)</i> , Vol. 90, pp. 1018-22 (1993)
	C272	Lefer, et al., "Mediation of Cardioprotection by Transforming Growth Factor- β ," <i>Science</i> , Vol. 249, pp. 61-64 (1990)
	C273	Lehmann, K. et al., "Effect of cilazapril on the proliferative response after vascular damage", <i>J. of Cardiovascular Pharmacology</i> , 22 (Suppl. 4), S19-24, (1993)
	C274	Lehmann-Bruinsma, et al., "Transforming Growth Factor B2 (TGF-B) Suppression of Smooth Muscle Cell (SMC) Proliferation After Balloon Angioplasty of Rat Carotid Arteries", <i>Clin. Res.</i> 42, Abstract No. 4A, (February 9-12, 1994)
	C275	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," <i>Abstracts, Proc. Am. Chem. Soc. Symp.</i> , In: <i>Biotechnol. Bioact. Poly.</i> , C.G. Gebelein, (ed.), pp. 359-268 (1992)
	C276	Liau and Chan, "Regulation of extracellular matrix RNA levels in cultured smooth muscle cells: relationship to cellular quiescence", <i>J. Cell Biol.</i> , 264:10315-10320 (1989)
	C277	Lichtlen et al., "Retardation of angiographic progression of coronary artery disease by nifedipine", <i>Lancet</i> , 335:1109-1113 (1990)
	C278	Lin, et al., "Expression Cloning of the TGF- β Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase," <i>Cell</i> , Vol. 68, pp. 775-785 (1992)
	C279	Lindkaer-Jensen, S., et al., "Inhibition of Salicylate and Lithium Absorption in the Human Intestine by Copper Sulfate", <i>Arch. Toxicol.</i> , 35, 175-179, (1976)
	C280	Lindner, "Vascular repair processes mediated by transforming growth factor-beta, <i>Z Kardiol</i> ", 90 Suppl 3:17-22 (2001)
	C281	Lippman and Mathews, "Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity", <i>Fed. Proc.</i> , 36:55-59 (1977)
	C282	Liu et al., "Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit", <i>Circulation</i> , 81(3): 1089-1093 (1990)
	C283	Lopez-Anaya, A., et al., "Pharmacokinetics and Pharmacodynamics in Copper Deficiency I", <i>Biological Trace Element Research</i> , 40, 161-176, (1994)
	C284	Lopez-Casillas, et al., "Beta-glycan Presents Ligand to the TGF β Signaling Receptor", <i>Cell</i> , 73, 1435-1444, (July 2, 1993)
	C285	Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", <i>Eur. J. Cancer Clin. Oncol.</i> , 21, 985-990, (1985)
	C286	Love, et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women," <i>Annals of Internal Medicine</i> , Vol. 115, No. 11, pp. 860-864 (1991)
	C287	Love, et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients with Node-Negative Breast Cancer," <i>J. of the National Cancer Institute</i> , Vol. 82, No. 16, pp. 1327-32 (1990)
	C288	Lowe, et al., "Coronary In-Stent Restenosis: Current Status and Future Strategies", <i>Journal of the American College of Cardiology</i> , 1992, Vol. 39 No. 2, pp. 183-193.
	C289	Luan et al., "Rapamycin is an effective inhibitor of human renal cancer metastasis", <i>Kidney Int.</i> , 63:917-926 (2003)
	C290	Lucas, C., et al., "The Autocrine Production of Transforming Growth Factor-B1 During Lymphocyte Activation", <i>The Journal of Immunology</i> , 145(5), 1415-1422, (1990)
	C291	Ludwig K. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiac Support", <i>The Society of Thoracic Surgeons</i> , (1996)

	C292	Luostarinen, R., et al., "Effect of Dietary Fish Oil Supplemented with Different Doses of Vitamin E on Neutrophil Chemotaxis in Healthy Volunteers", <i>Nutrition Research</i> , 12, 1419-1430, (1992)
	C293	Lutgens et al., "Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:975-982 (2002)
	C294	Lyons et al., "Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin", <i>J. Cell. Biol.</i> , 110:1361-1367 (1990)
	C295	Madri et al., "Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin", <i>Lab. Invest.</i> , 60:755-764 (1989)
	C296	Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", <i>Current Medicinal Chemistry</i> , 1, 61-104, (1994)
	C297	Maione, Theodore E. and Sharpe, Richard J. "Development of angiogenesis inhibitors for clinical applications" <i>TIPS- Nov. 1990</i> [Vol. 11]
	C298	Majack, "Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures", <i>J. Cell Biol.</i> , 105:465-471 (1987)
	C299	Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-B", <i>The Journal of Cell Biology</i> , 111, 239-247, (1990)
	C300	Majesky, M.W., et al., "Production of Transforming Growth Factor beta1 During Repair of Arterial Injury", <i>J. Clin. Invest.</i> , 88, 904-910, (1991)
	C301	Mambetisaeva, E.T., et al. "Effect of New Synthetic Cholesterol Derivatives on Cholesterol Metabolism in Cultured Rabbit Hepatocytes", <i>Biokhimiya</i> (Russia), 58, Translation, Plenum Publishing Corporation, 1126-1132, (1993)
	C302	Mang, Tien-Dung Duc, "Distribution to Normal and Tumor Tissues of Cytochalasin B After Intravenous Administration in Mice," Thesis Submitted for Honors B.S. in Biology, Syracuse University
	C303	Mansoor Amiji and Kinam Park, "Surface Modification of Polymeric Materials with Poly (ethylene oxide), Albumin, and Heparin For Reduced Thrombogenicity," Purdue University, School of Pharmacy, West Lafayette, IN 47907
	C304	Manucci, P.M., et al., "Effect of Tamoxifen on Measurements of Hemostasis in Healthy Women", <i>Arch. Intern. Med.</i> , 156, 1806-1810, (1996)
	C305	Marx and Marks, "Bench to Bedside: The development of rapamycin and its application to stent restenosis", <i>Circulation</i> 104:852-55 (2001)
	C306	Massague and Wotton, "Transcriptional control by the TGF-beta/Smad signaling system", <i>EMBO J.</i> , 19(8):1745-54 (2000)
	C307	Massague et al., "Type beta transforming growth factor is an inhibitor of myogenic differentiation", <i>Proc. Natl. Acad. Sci.</i> , 83:8206-8210 (1986)
	C308	Massagué, Joan, "The Transforming Growth Factor-B; Family", <i>Annu. Rev. Cell Biol.</i> Vol. 6, pp. 597-641 (1990)
	C309	Massague, "Subunit structure of a high-affinity receptor for type beta-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex", <i>J. Biol. Chem.</i> , 260(11):7059-7066 (1985)
	C310	McAuslan, B.R., et al., "Cellular and Molecular Mechanisms in Angiogenesis", <i>Trans. Ophthal. Soc. U.K.</i> , 100, 354-358, (1980)
	C311	McCaffrey et al., "Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restenotic vascular cells," <i>J Clin Invest</i> , 100:2182-2188 (1997)
	C312	McCaffrey et al., "Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity," <i>J. Exp. Med.</i> , 167:163-174 (1988)
	C313	McCaffrey et al., "Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1", <i>J. Clin. Invest.</i> , 96:2667-2675 (1995)
	C314	McCaffrey, "TGF-betas and TGF-beta receptors in atherosclerosis," <i>Cytokine and Growth Factor Rev.</i> , 11:103-114 (2000)
	C315	McCaffrey, T.A., et al., "Fucoidan is a Non-Anticoagulant Inhibitor of Intimal Hyperplasia", <i>Biochemical and Biophysical Research Communications</i> , 184, 773-781, (1992)
	C316	McCague, R., et al., "An Efficient, Large Scale Synthesis of Idoxifene ((E)-1(4- (2- (N-pyrrolidino) ethoxyl) -1-(4-iodophenyl) -2-phenyl-1-butene)", <i>Organic Preparations and Proc. Int.</i> , 26, 343-346, (1994)
	C317	McCague, R., et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled Idoxifene and Axiridinyl 4-Iodotamoxifen.", <i>J. Labelled Compounds and Pharmaceuticals</i> , 34, 297-302, (1994)
	C318	McCarroll, et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-β (TGF-β) by Endothelial Cells in Culture, <i>Clin. Chem.</i> Vol. 36, No. 6, pp. 1152 (1990) Abstract No. 0934
	C319	McClean, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", <i>Nature</i> , 330, 132-137 (1987), 132-137, (1987)
	C320	McCormick, et al., "Retinoid-Tamoxifen Interaction in Mammary Cancer Chemoprevention," <i>Carcinogenesis</i> , Vol. 7, No. 2, pp. 193-196 (1986)
	C321	McDonald, C.C., et al., "Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial", <i>BMJ</i> , 311, 977-980, (October 14, 1995)
	C322	McDonald, et al., "Fatal Myocardial Infarction in the Scottish Adjuvant Tamoxifen Trial," <i>BMJ</i> , Vol. 303 pp. 435-437 (1991)

	C323	McDonnell, D.P., et al., "Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of Anti estrogens", <i>Molecular Endocrinology</i> , 9, 65-669, (June 1995)
	C324	McMurray et al., "A standardised method of culturing aortic explants, suitable for' the study of factors affecting the phenotypic modulation, migration and proliferation of aortic smooth muscle cells," <i>Atherosclerosis</i> , 86:227-237 (1991)
	C325	Meiser et al., "Effectsof Cyclosporin, Fk506, and Rapamycin on Graft-Vessel Disease", <i>The Lancet</i> , 338, 1297-1298 (1991)
	C326	Merck Index,, (Susan Budavari et al, ed.) 1989, p 1435
	C327	Merrilees and Scott, "Antisense S-oligonucleotide against transforming growth factor-beta 1 inhibits proteoglycan synthesis in arterial wall," <i>L Vase. Res.</i> 31:322-329 (1994)
	C328	Merrilees et al., "Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries, 3". <i>Vasc. Res.</i> 37:50-60 (2000)
	C329	Merrilees, et al., "Synthesis of TGF-β ₁ by Vascular Endothelial Cells is Correlated with Cell Spreading," <i>J. Vasc. Res.</i> , Vol. 29, pp. 376-384 (1992)
	C330	Metcalfe et al., "Calcium and cell proliferation," <i>Br. Med.. Bull.</i> , 42(4):405-4t2 (1986)
	C331	Michael N. Helmus, "Materials Selection, Chapter 2," <i>Encyclopedic Handbook of Biomaterials and Bioengineering, Part A: Materials</i> , Vol. 1 (1995)
	C332	Michael N. Helmus, "Materials Selection, Chapter 6, <i>Cardiovascular Pathol.</i> 2(3)(Suppl.):53s-71s (July-Sept. 1993)
	C333	Michael N. Helmus, "Materials Selecton for Medical Devices," <i>Spectrum</i> , 1-21, (July 30, 1993)
	C334	Michael N. Helmus, "Medical Device Design--A Systems Approach: Central Venous Catheters", (1990)
	C335	Michael N. Helmus, "Opportunities for Biomaterials," <i>DH Reports</i> , (February 1995)
	C336	Michael N. Helmus, "Technological Advances in Thromboresistant Materials," <i>Spectrum</i> , 1-13 (June 19, 1990)
	C337	Michael N. Helmus, "Thromboresistant Biomaterials: Technical Developments and Applications," <i>Spectrum</i> , (Sept. 12, 1990)
	C338	Milner, M.R., et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", <i>Am. J. Cardiol.</i> , 64, 294-299 (1989)
	C339	Mirjalili, N. et al., "Methyl Jasmonate Induced Production of Taxol in Suspension Cultures of <i>Taxus Cuspidata</i> : Ethylene Interaction and Induction Models", <i>Biotechnol. Prog.</i> , 12, 110-118, (1996)
	C340	Mirjalili, N., et al., "Gas Phase Composition Effects on Suspension Cultures of <i>Taxus cuspidata</i> ", <i>Biotechnology and Bioengineering</i> , 48, 123-132, (1995)
	C341	Mitchell, L.L., et al., "Copper Deficiency Depresses Rat Aortae Superoxide Dismutase Activity and Prostacyclin Synthesis", <i>Prostaglandins</i> , 35, 977-986, (1988)
	C342	Molling, K., "Naked DNA for Vaccine or Therapy", <i>J. Mol. Med.</i> , 75, 242-246, (1997)
	C343	Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Adducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Adducts Formed in Vivo", <i>Cancer Research</i> , 56, 53-57, (Jan. 1, 1996)
	C344	More, R.S., et al., "A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation", <i>Chemical Abstracts</i> , Vol. 120, No. 22, (May 30, 1994)
	C345	Morris et al., "Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells," <i>Transplant Proc</i> , 27:430-31 (1995)
	C346	Morris, R.E., "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides", <i>Transplantation Reviews</i> , 6, 39-87, (1992)
	C347	Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", <i>Transplantation Proceedings</i> , 23, 19-25, (1991)
	C348	Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system," <i>Biochem J.</i> , 343:125-133 (1999)
	C349	Mosedale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its relationship to TGF-β in vivo, DJG 005652-005910 (1998) and all references therein
	C350	Moses and Langer "Inhibitors of angiogenesis". <i>Bio/Technology</i> . 9:630-634, 1991
	C351	Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", <i>J. Steroid Biochem</i> , 34, 1-6 (1989)
	C352	Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", <i>Molecular Pharmacology</i> , 39, 421-428, (1991)
	C353	Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", <i>Endocrinology</i> , 116, 1071-1078, (1985)
	C354	Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canola Oil and Added Copper to Alter the Unsaturated:Saturated Ration of Pork Fat", <i>J. Anim. Sci.</i> , 70, 1417-1423, (1992)
	C355	Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fatty Acid in Man", <i>Atherosclerosis</i> , 47, 71-75, (1983)
	C356	Nakagawa, et al., "A Case of Acute Myocardial Infarction Intracoronary Arteries Due To Hormone Therapy.",

		Angiology, 45, 333-338, (May 1994)
	C357	Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14(3), 1018-1026, (1996)
	C358	Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vascular restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1994)
	C359	Nikol, et al., "Expression of Transforming Growth Factor β_1 is Increased in Human Vascular Restenosis Lesions," J. Clin. Invest., Vol. 90, pp. 1582-92 (1992)
	C360	O'Connor-McCourt, et al., "Latent Transforming Growth Factor β in Serum: A Specific Complex with γ_2 -Macroglobulin," The Journal of biological Chemistry, Vol. 262, No. 29, pp. 14090-14099 (1987)
	C361	O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and Its Used as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996)
	C362	O'Keefe Jr. et al., "Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty". JACC, 19(7): 1597-1600, 1992
	C363	Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity and Possible Opioid Receptor Activation", Agents and Actions, 21, 130-144, (1987)
	C364	Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989)
	C365	Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liver DNA of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996)
	C366	Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertrophy in Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988)
	C367	Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis", Biochem Mol. Biol. Intern, 35, 117-124, (1995)
	C368	Palmaz et al., "Balloon Expandable Intraluminal Grafting of Normal and Abnormal Renal Arteries: Experimental Study," Radiology 1986 Nov; 161 (P):40-41 Abstract 85.
	C369	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension," A JR 1986 Dec; 147:1251-54.
	C370	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. J. Roentgenol. 1985;145:821-825.
	C371	Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov; 157(P):66 Abs 130.
	C372	Palmaz et al., "Normal and Stenotic Renal Arteries: Experimental Balloon-expandable Intraluminal Stenting," Radiology 1987 Sept; 164(3):705-708.
	C373	Palmaz et al., "Removable Biliary Endoprosthesis," Am, J. Roentgenol. 1983;140(4):812-4.
	C374	Palmaz, et al., "Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting," Radiology 1986 Sept; 160:723-726.
	C375	Palmaz, et al., "Expandable Intrahepatic Portocaval Shunt Stents in Dogs with Chronic Portal Hypertension," American Roentgen Ray Soc'y 1986 Annual Meeting, Washington, D.C., (BT 000079) (April 13-18, 1986).
	C376	Palmaz, et al., "Intravascular Stents: Basic Physical and Biological Properties, Endoluminal Treatment: The Different Techniques." Editors Michel Henry, Max Amor, Edward B. Diethrich and Barry Katzen. Published by Springer Verlag; 4:149-158 (1997).
	C377	Palmaz, J.C. "Balloon-Expandable Intravascular Stent," A JR 1988 June; 150:1263-1269.
	C378	Palmaz, J.C. "Expandable Intraluminal Graft: A Preliminary Study," Radiology 1984 Nov;153(P):329 Abs. 993.
	C379	Pandey, B.L., et al., "A Study of the Effects of Tamrabhasma, an Indigenous Preparation of Copper on Experimental Gastric Ulcers and Secretion", Indian Journal of Experimental Biology, 21, 258-264, (1983)
	C380	Pardoll, D., et al., "Exposing the Immunology of Naked DNA Vaccines", Immunity, 3, 165-169, (1995)
	C381	Parthasathay, S., et al., "A Role for Endothelial Cell Lipoxxygenase in the Oxidative Modification of Low Density Lipoprotein", Proc. Nat'l Acad. Sci., USA, 86, 1046-1050, (1989)
	C382	Pedron, N. et al., "The Effect of Acetylsalicylic Acid on Menstrual Blood Loss in Women with IUDs", Contraception, 36, 295-303, (1987)
	C383	Peng et al., "The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation," Mol. Cell., 22:5575-84 (2002)
	C384	Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science, 273, 1171, (Aug. 30, 1996)
	C385	Peress, N.S., et al., "Differential Expression of TGF-B1, 2 and 3 Isotypes in Alzheimer's Disease : A Comparative Immunohistochemical Study with Cerebral Infarction, Aged Human and Mouse Control Brains", Journal of Neuropathology and Experimental Neurology, 54, 802-811, (November 1995)
	C386	Peress, N.S., et al., "Glial Transforming Growth Factor (TGF) -B Isotypes in Multiple Sclerosis: Differential Glial Expression of TGF- B1, 2, and 3 Isotypes in Multiple Sclerosis", Journal of Neuroimmunology, 71, 115-123, (1996)
	C387	Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF - kb RelA Involves Transforming Growth Factor Beta", Molecular and Cellular Biology, 14, 5326-5332, (1994)
	C388	Pfister, W.R. et al., "Silicone Based Sustained and Controlled Release Drug Delivery Systems", 1985, 30 th National SAMPE Symposium and Exhibition, Anaheim, CA, March 19-21, 1985, pp. 490-498 (1985)

	C389	Pinto, H.C., et al., "Tamoxifen-associated Steatohepatitis C Report of Three Cases", <i>Journal of Hepatology</i> , 23, 95-97, (1995)
	C390	Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet #172
	C391	Potter et al., "A mechanism hypothesis for DNA adduct formation following hepatic oxidative metabolism," <i>Carcinogenesis</i> , 15, 439-442 (1994)
	C392	Powell et al., "Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury," <i>Science</i> , 245:186-188 (1989)
	C393	Presentation at The Society of CV & Interventional Radiology's Twelfth Annual Course On "Diagnostic Angiography and Interventional Radiology." Includes: "The Current Status of Vascular Prostheses" by Julio Palmaz at 118-120 (March 23 - 26 1987).
	C394	Program and abstracts of the Seventh International Conference on the Adjuvant Therapy of Cancer, held in Tuscon, Arizona on March 10-13, 1993
	C395	Pupita, G., et al., "Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina Pectoris", <i>The New England Journal of Medicine</i> , 323, 514-520, (1990)
	C396	Rainsford, K.D., et al., "Concerning the Merits of Copper Aspirin as a Potential Anti-Inflammatory Drug", <i>J. Pharm. Pharmac.</i> , 28, 83-86, (1976)
	C397	Rainsford, K.D., et al., "Gastric Mucus Effusion Elicited by Oral Copper Compounds: Potential Anti-Ulcer Activity", <i>Experientia</i> , 32, 1172-1173, (1976)
	C398	Raisz, L.G., "Estrogen and Bone: New Pieces to the Puzzle", <i>Nature Medicine</i> , 2, 1077-1078, (1996)
	C399	Raloff, "Tamoxifen Puts Cancer on Starvation Diet", <i>Science News</i> , 146, 292, (November 5, 1994)
	C400	Ray, P., et al., "Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-6B by the estrogen receptor", <i>FEBS Letters</i> , 409, 79-85, (1997)
	C401	Razavi, M., "Unusual Forms of Coronary Artery Disease", <i>Cleveland Clinic Consultations</i> , 7, 25-46, (1975)
	C402	Recchia, F., et al., "Interferon-beta, Retinoids, and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study", <i>Journal of Interferon and Cytokine Research</i> , 15, 605-610, (1995)
	C403	Reckless, J., et al., "Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice", <i>Circulation</i> , 95, 1542-1548, (1997)
	C404	Reilly et al., "Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor," <i>J. Cell Physiol.</i> , 131 :t 49-157 (1987)
	C405	Reilly, C.F., "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T Antigen Possess Defined Smooth Muscle Cell Characteristics Including Growth Inhibition by Heparin", <i>Journal of Cellular Physiology</i> , 142, 342-351, (1990)
	C406	Reis, G.J., et al., "Randomized Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", <i>The Lancet</i> , 177-181, (1989)
	C407	Ribeiro, G., et al., "Adjuvant Tamoxifen for Male Breast Cancer (MBC)", <i>Br. J. Cancer</i> , 65, 252-254, (1992)
	C408	Rieckmann, P., et al., "Tumor Necrosis Factor-a Messenger RNA Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Associated with Disease Activity", <i>Ann. Neurol</i> , 27, 82-88, (1996)
	C409	Roberts et al., "Type beta transforming growth factor: a bifunctional regulator of cellular growth," <i>Proc. Natl. Acad. Sci.</i> , 82:119-123 (1985)
	C410	Robinson, J.R. (ed), "Sustained and Controlled Release Drug Delivery Systems," New York, Marcel Dekker (1978). Chapters 1-2, 4, and 7-9.
	C411	Roche Lexikon Medizin, Urban und Schwarzenberg, 1984, page 69 "Antibiotika", and page 515 "Fibrin"
	C412	Rompp Chemie-Lexikon, 9 th ed., pages 206-208, pages 1350 and 1351
	C413	Rompp, Chemie-Lexikon, 8 th ed., 1987, page 2633 "Mitosehemmer"
	C414	Ross, et al., "Chronic Inflammation, PDGF, TGF, and Smooth Muscle Proliferation, Abstracts from the 20 th Annual Meeting of the Keystone Symposia on Molecular Biology, Session on Molecular Mechanisms of Vascular Disease, J. Cell Biochem. S15C, Abstract No. G006, p. 96 (1991)
	C415	Roubin, "Intracoronary Stenting of Canine Coronary Arteries After Percutaneous Coronary Angioplasty (PTCA)," <i>Circulation</i> 1986 Oct;74(Supp. II-458):1825 Abstract.
	C416	Rowinsky et al., "Taxol: Twenty years Later, the Story Unfolds," <i>Journal of the National Cancer Institute</i> , 1991, Vol 83 No. 24 pp 1778-1781
	C417	Rutqvist, L.E., et al., "Cardiac and Thromboembolic Morbidity Among Postmenopausal Women with Early-Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen", <i>Journal of the National Cancer Institute</i> , 85, 1398-1406, (1993)
	C418	Ruygrok and Serruys, "From Bench to Bedside, Intracoronary Stenting, From Concept to Custom," <i>Circulation</i> 1996; 94:882-890
	C419	Ryan et al., "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury," <i>J. Vase. Res.</i> , 40:37-46 (2003)
	C420	Saarto, T., et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", <i>Journal of Clinical Oncology</i> , 14, 429-433, (February 1996)

	C421	Sabatini et al., "RAFT1: a mammalian protein that binds to FK.BP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", <i>Cell</i> , 78:35-43 (1994)
	C422	Saito, H., et al., "Influence of Maternal Drug Metabolism on the Fetal Toxicity Induced by Acetylsalicylic Acid", <i>The Journal of Toxicological Sciences</i> , 7, 177-184, (1982)
	C423	Sanchez, et al., "Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence," <i>J. Of Biomedical Materials Research</i> , pp. 655-661 (1995)
	C424	Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", <i>Carcinogenesis</i> , 17, 1051-1056, (1996)
	C425	Schatz et al., "Balloon Expandable Intravascular Stents in Diseased Human Cadaver Coronary Arteries," <i>Circulation</i> 1987 Oct;70(4): Abstract 0102.
	C426	Schatz et al., "Balloon-expandable Intra-coronary Stents In The Adult Dog," <i>Circulation</i> 1987 Aug; 76(2):450-457.
	C427	Schatz, et al., "Balloon Expandable Intracoronary Stents In Dogs," <i>Circulation</i> 1986 Oct;74(Supp. II-458): 1824 Abstract,
	C428	Schatz, et al., "Clinical Experience with the Palmaz-Schatz Stent: Initial Results of A Multicenter Study," <i>Circulation</i> 1991 Jan;83(1): 148-161.
	C429	Schatz, R.A. Introduction to Intravascular Stents, <i>Cardiology Clinics</i> 1988 Aug;6(3):357-72.
	C430	Schlaak, J.F., et al., "Different Cytokine Profiles in the Synovial Fluid of Patients with Osteoarthritis, Rheumatoid Arthritis and Seronegative Spondylarthropathies", <i>Clinical and Experimental Rheumatology</i> , 14, 155-162, (1996)
	C431	Schmidt, E.B., et al., "Long-Term Supplementation with n-3 Fatty Acids, II: Effect on Neutrophil and Monocyte Chemotaxis", <i>Scand. J. Clin. Lab. Invest.</i> , 52, 229-236, (1992)
	C432	Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothrax and Pulmonary Lymphangiomyomatosis Clinical Picture Diagnoses and Theory.", <i>Chiracq</i> , 61, 301-303 (1990); reported in <i>Biosis</i> , 90, 432367 (1990), English abstract only
	C433	Schulick et al., "Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia," <i>PNAS</i> 95:6983-6988 (1998)
	C434	Schwartz, C.J., et al., "The Pathogenesis of Atherosclerosis: An Overview", <i>Clin. Cardiol.</i> , 14, 1-1--1-16, (1991)
	C435	Schwartz, G.G., et al., "Pathophysiology of Chronic Stable Angina", In: <i>Atherosclerosis and Coronary Artery Disease</i> , V. Fuster, et al., (eds.), Lippencott-Raven Publishers, Philadelphia, pp. 1386-1400, (1996)
	C436	Sedlacek, S. "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", <i>Breast Cancer Research and Treatment</i> , 14, Abstract No. 82, 153, (1989)
	C437	Sehgal et al., "Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization." <i>J. Antibiot.</i> , 28:727-32 (1975)
	C438	Sehgal, "Sirolimus: its discovery, biological properties, and mechanism of action." <i>Transplant. Proc.</i> , 35(3 Suppl):7S-148 (2003)
	C439	Serruys et al., "The new angiotensin converting enzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty: the results of the MERCATOR trial," <i>JACC</i> 19:258A, Abstract 783-2 (1992)
	C440	Shanahan and Weissberg, "Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo," <i>Arterioscler. Thromb. Vase. Biol.</i> , 18(2):333-338 (1998)
	C441	Shapiro, L.M., "Echocardiographic Features of Impaired Ventricular Function in Diabetes Mellitus", <i>British Heart Journal</i> , 47, 439-444, (1982)
	C442	Shemon, et al., "Tamoxifen Decreases Lipoprotein(a) in Patients with Breast Cancer.", <i>Metabolism</i> , 43, 531-532, (May 1994)
	C443	Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipoprotein(a) Concentration in Healthy Postmenopausal Women", <i>Arteriosclerosis and Thrombosis</i> , 14, 1589-1593, (1994)
	C444	Shewmon, et al., "Tamoxifen Lowers Lp(a) in Males with Heart Disease," <i>Supplement I Cir.</i> , Vol. 86, No. 4, p. 1345 (1992)
	C445	Shimaoka, I., et al., "Purification of a Copper Binding Peptide from the Mushroom <i>Grifola Frondosa</i> and Its Effect on Copper Absorption", <i>J. Nutr. Biochem.</i> , 4, 33-38, (1993)
	C446	Shou et al., "Cardiac defects and altered ryanodine receptor function in mice lacking FK-BP 12," <i>Nature</i> , 391 (6666):489-92 (1998)
	C447	Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," <i>N. Engl. J. Med.</i> , Mar. 19, 1987, Vol. 316, No. 12, pp.701-06
	C448	Sigwart, U., Frank, G.I., "Bioabsorbable, Drug-Eluting, Intracoronary Stents: Design and Future Applications," <i>Coroinary Stents</i> . Springer-Verlag (1992)
	C449	Sigwart, Ulrich, "The Self Expanding Mesh Stent" <i>Textbook of Interventional Cardiology</i> , (Eric J. Topol, ed) 1990, Chapter 29, pp 605-622
	C450	Silber, S. "Drug-eluting stents: aktueller Stand", internet article on http://sigmund-silber.com/deutsch/varia/var-2003/03-09-5-Silber-Chemnitz.pdf of August 6, 2003
	C451	Singh, et al., "Phylogenetic Analysis of Platelet-derived Growth Factor by Radio-Receptor Assay," <i>The Journal of Cell Biology</i> , Vol. 95, pp. 667-671 (1982)
	C452	Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", <i>Anticancer Res.</i> , 14, 2237-2244, (1994)
	C453	Soderberg, L.S., et al., "Copper (II) (3,5-Diisopropylsalicylate) sub2 Accelerates Recovery of B and T Cell Reactivity Following Irradiation", <i>Scand J. Immunol.</i> , 26, 495-502, (1987)

	C454	Soderberg, L.S., et al., "Copper (II) sub2(3, 5-diisopropylsalicylate) sub4 Stimulates Hemopoiesis in Normal and Irradiated Mice", <i>Exp. Hematol.</i> , 18, 577-580, (1988)
	C455	Soderberg, L.S., et al., "Postirradiation Treatment with Copper (II) sub2 (3,5-diisopropylsalicylate) sub4 Enhances Radiation Recovery and Hemopoietic Regeneration", <i>Exp. Hematol.</i> , 18, 801-805, (1990)
	C456	Soderberg, L.S., et al., "Radiation Recovery Agents", <i>DN & P</i> , 3, 600-605, (1990)
	C457	Song, J., et al., "Tamoxifen (Estrogen Antagonist) Inhibits Voltage-Gated Calcium Current and Contractility in Vascular Smooth Muscle from Rats", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 227, 1444-1453, (1996)
	C458	Sorenson, J.R., "Copper Complexes Offer a Physiological Approach to Treatment of Chronic Disease", <i>Progress in Medicinal Chemistry</i> , 26, 437-568, (1989)
	C459	Sorenson, J.R., "Essential Metalloelement Metabolism and Radiation Protection and Recovery", <i>Radiation Research</i> , 132, 19-29, (1992)
	C460	Sorenson, J.R., "Pharmacological Activities of Copper Compounds", In: <i>Handbook of Metal-Ligand Interactions in Biological Fluids -- Bioinorganic Medicine</i> , vol. 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139, (1995)
	C461	Sorenson, J.R., "Radiation Protection and Radiation Recovery with Essential Metalloelement Chelate", <i>P.S.E.B.M.</i> , 210, 191-204, (1995)
	C462	Sorenson, J.R., "The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", <i>Journal of Pharmaceutical Sciences</i> , 73, Open Forum, 1875-1878, (1984)
	C463	Sorenson, J.R., et al., "Antieoplastic Activities of Some Copper Salicylates", In: <i>Trace Substances in Environmental Health</i> , vol. XVI, Hemphill, D.D., (ed.), University of Missouri, Columbia, 362-369, (1982)
	C464	Sorenson, J.R., et al., "Bis (3, 5-diisopropylsalicylato) copper (II), a Potent Radioprotectant with Superoxide Dismutase Mimetic Activity", <i>J. Med. Chem.</i> , 27, 1747-1749, (1984)
	C465	Sorenson, J.R., et al., "Copper Complexes as 'Radiation Recovery' Agents", <i>Chemistry in Britain</i> , 25, 169-171, (1989)
	C466	Sorenson, J.R., et al., "Copper-, Iron-, Manganese- and zinc-3, 5-diisopropylsalicylate Complexes Increase Survival of Gamma-Irradiated Mice", <i>Eur. J. Med. Chem.</i> , 28, 221-229, (1993)
	C467	Sousa et al., "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up," <i>Circulation</i> , 104:2007-i 1 (2001) (CYP228071-228075)
	C468	Sousa et al., "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries," <i>Circulation</i> . 107(3):381-3 (2003) (BSX 024170-024172)
	C469	Sousa, J.E. et al., "New Frontiers in Cardiology Drug-Eluting Stents: Part I", <i>Circulation</i> , 2003, 107:2274-2279,
	C470	Southgate and Newby, "Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP," <i>Atherosclerosis</i> , 82:113-123 (1990)
	C471	Srivastava, K.C., "Effects of Dietary Fatty Acids, Prostaglandins and Related Compounds on the Role of Platelets in Thrombosis", <i>Biochem. Exp. Biol.</i> , 16, 317-338, (1980)
	C472	Standley, P.R., et al., "Tamoxifen (an Antiestrogen) Reduces K Positive- and Agonist-Induced Vascular Contractility in Rat Resistance Vessels", Abstract No. 159 (Source and Date Unavailable)
	C473	Stevenson, F., et al., "Idiotypic DNA Vaccines against B-cell Lymphoma", <i>Immunological Reviews</i> , 145, 221-228, (1995)
	C474	Stork, G., et al., "Total Synthesis of Cytochalasin B", <i>Journal of the American Chemical Society</i> , 100, 7775-7777, (1978)
	C475	Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependant Effect on EFG and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", <i>J. Cellular Biochem, Supplement 18A</i> , Abstract No. A321, 288, (1994)
	C476	Streptetti, A.V., et al., "Formation of Myointimal Hyperplasia and Cytokine Production in Experimental Vein Grafts", <i>Surgery</i> , 123(4), 461-469, (1998)
	C477	Streuli, et al., "Extracellular Matrix Regulators Expression of the TGF- β 1 Gene," <i>The J. of Cell Biol.</i> Vol. 120, No. 1, pp. 253-260 (1993)
	C478	Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Estrogen Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rat", <i>Endocrinology</i> , 112, 425-434, (1983)
	C479	Swain, "Blazing new paths for product introductions," <i>Medical Device & Diagnostic Industry</i> , Sept. 2003, p. 68-81
	C480	Szekanecz, Z., et al., "Increased Synovial Expression of Transforming Growth Factor (TGF) -B Receptor Endoglin and TGF- B1 in Rheumatoid Arthritis: Possible Interaction in the Pathogenesis of the Disease", <i>Clinical Immunology and Immunopathology</i> , 76, 187-194, (August 1995)
	C481	Takashima, K. et al., "The Hypocholesterolemic Action of TA-7552 and its Effects on Cholesterol Metabolism in the Rat", <i>Atherosclerosis</i> , 107, 247-257, (1994)
	C482	Tanaka et al., "Ialpa 25 (OH) 303 Exerts Cytostatic effects on Murine Osteosarcoma Cells and Enhance Cytocidal Effects on Anticancer Drugs" <i>Clinical Orthopaedics and related Research</i> no. 247 1989 pgs. 290-296
	C483	Tanenbaum, S.W., "Microbiological, Preparative and Analytical Aspects of Cytochalasin Production", In: <i>Cytochalasins -- Biochemical and Cell Biological Aspects</i> , Tanenbaum, S.W., (ed.), Elsevier/North-Holland Biomedical Press, 2-14, (1978)
	C484	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". <i>Arthritis and Rheumatism</i> , 36 (9) Suppl.:S45, 1993

	C485	Teirstein (ed.), "Coronary Stents: pros and cons," <i>Coronary Artery Disease</i> , 5:561-600 (1994).
	C486	Tessari et al., "Antiproliferative activity of unfractionated heparin on a human smooth muscle cell line, <i>Pharmacol. Res.</i> , 21:145-6 (1989)
	C487	Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine Contraceptive Devices", <i>J. Reprod. Fert.</i> , 63, 257-261, (1981)
	C488	Thompson, J.T., et al., "Comparison of Recombinant Transforming Growth Factor-beta -2 and Placebo as an adjunctive Agent for Macular Hole Surgery", <i>Ophthalmology</i> , 15(4), 700-706, (1998)
	C489	Thompson, N.L., et al., "Expression of Transforming Growth Factor-B1 in Specific Cells and Tissue of Adult and Neonatal Mice", <i>Journal of Cell Biology</i> , 108, 661-669, (1989)
	C490	Tong et al., "Non-Thrombogenic Hemofiltration System for Acute renal failure Treatment: <i>ASAIO Trans.</i> 38: M702-M706 (1992)
	C491	Toomasian et al., "Evaluation of Duraflon II Heparin Coating in Prolonged Extracorporeal Membrane Oxygenation", <i>ASAIO Trans</i> 34: 410-14 (1988)
	C492	Topol, E. et al., "Frontiers in Interventional Cardiology" <i>Circulation</i> , 1998, 98:1802-1820,
	C493	Treasure, C.B., et al., "Hypertension and Left Ventricular Hypertrophy Are Associated With Impaired Endothelium-Mediated Relaxation in Human Coronary Resistance Vessels", <i>Circulation</i> , 87, 86-93, (1993)
	C494	Treiber, A., et al., "Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization of Thiophene S-Oxide Dimers and Evidence for Thiophene S-Oxide as an Intermediate in Thiophene Metabolism in vivo and In Vitro", <i>J. Am. Chem. Soc.</i> , 119, 1565-1571, (1997)
	C495	Tucker et al., "Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor," <i>Science</i> , 226:705-707 (1984)
	C496	Ulman, K.L. et al., "Drug Permeability of Modified Silicone Polymers", <i>J. Controlled Release</i> , 10:251-260 (1989)
	C497	Van Der Giessen, <i>et al.</i> , "Coronary Stenting With Polymer-Coated And Uncoated Self-Expanding Endoprosthesis In Pigs" <i>Coron. Art. Disease</i> 1992; 3:631-40
	C498	Van Der Giessen, <i>et al.</i> , "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs" " <i>Circulation</i> 82:III-542 (1990)
	C499	Van Sickle, W.A., et al., "An Alternative Mechanism for the Inhibition of Cholesterol Biosynthesis in HepG2 Cells by N- [(1,5,9) -Trimethyldecyl] -4alpha, 10-dimethyl 8-aza-trans-decal-3beta-ol (MDL 28, 815)", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 267, 243-1249, (1993)
	C500	Vargas, et al., "Oestradiol Inhibits Smooth Muscle Cell Proliferation of Pig Coronary Artery," <i>Br. J. Pharmacol.</i> , Vol. 109, pp. 612-617 (1993)
	C501	Vawter, M.P., et al., "TGF B1 and TGF B2 Concentrations are Elevated in Parkinson's Disease in Ventricular Cerebrospinal Fluid", <i>Experimental Neurology</i> , 141, 313-332, (1996)
	C502	Vidensek N., et al., "Taxol Content in Bark, Wood, Root, Leaf, Twig, and Seedling from Several Taxus Species", <i>Journal of Natural Products</i> , 53, 1609-1610, (Nov./Dec., 1990)
	C503	Voisard, R., et al., "Search for new strategies for prevention of restenosis after angioplasty: the effect of cytostatic drugs on cell migration of re-stenosing human plaques cells in vitro". <i>Vasa Suppl.</i> 1992; 35: 132-3 [Article in German]
	C504	Von Schacky, C., et al., "Long-Term Effects of Dietary Marine omega-3 Fatty Acids upon Plasma and Cellular Lipids, Platelet Function, and Eicosanoid Formation in Humans", <i>J. Clin. Invest.</i> , 76, 1626-1631, (1985)
	C505	Wakefield, et al., "Latent Transforming Growth Factor β from Human Platelets: A High Molecular Weight Complex Containing Precursor Sequences," <i>The Journal of Biological Chemistry</i> , Vol. 263, No. 16, pp. 7646-7654 (1988)
	C506	Wakefield, et al., "Recombinant Latent Transforming Growth Factor I Has a Longer Plasma Half-Life in Rats than Active Transforming Growth Factor, I, and a Different Tissue Distribution," <i>The Journal of Clinical Investigation</i> , Inc., Vol. 86, pp. 1976-1984 (1990)
	C507	Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries", <i>Circulation</i> , 92, 1383-1386, (1995)
	C508	Wallace, et al., "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," <i>RADIOLOGY</i> 1986 Feb;158(2):309-12.
	C509	Wallace, J.M., et al., "Dietary Fish Oil Supplementation Alter Leukocyte Function and Cytokine Production in Healthy Women", <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , 15, 185-189, (1995)
	C510	Waller et al., "Crackers, Breakers, Stretchers, Drillers, Scrappers, Shavers, Burners, Welders and Melters: The Future Treatment of Atherosclerotic Coronary Artery Disease?" <i>A Clinical-Morphologic Assessment</i> , <i>JACC</i> 13:969-87 (1989)
	C511	Waller et al., "Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia," <i>Transpl. Int.</i> 17:9-14 (2004)
	C512	Waller et al., "Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration," <i>Transplant Proc.</i> 37(1): 164-6 (2005).
	C513	Waller, B.F. X.L., et al., "Atherosclerotic and Nonatherosclerotic Coronary Artery Factors in Acute Myocardial Infarction", In: <i>Acute Myocardial Infarction</i> , Pepine, C.J., (ed.), F.A. Davis Company, Philadelphia, 29-104, (1989)

	C514	Walterberger, "Modulation of growth factor action: implications for the treatment of cardiovascular diseases," <i>Circulation</i> , 96:4083-4094 (1997)
	C515	Wang, X.L., et al., "Circulating Transforming Growth Factor Beta and Coronary Artery Disease", <i>Cardiovascular Research</i> , 34, 404-410, (1997)
	C516	Ward et al., "Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries," <i>Atherosclerosis</i> , 137:267-
	C517	Ward et al., "Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting," <i>Arterioscler. Thromb. Vasc. Biol.</i> 22:940-948 (2002);
	C518	Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", <i>J. Clin. Invest.</i> , 93, 2106-2113, (May 1994)
	C519	Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", <i>Lancet</i> , 347, 305-307, (Feb. 3 1996)
	C520	West, G.B., "Comments on 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", <i>Journal of Pharmaceutical Sciences</i> , 74, Open Forum, 700, (1985)
	C521	West, G.B., "Testing for Drugs Inhibiting the Formation of Gastric Ulcers", <i>Journal of Pharmacological Methods</i> , 8, 33-37, (1982)
	C522	Wickremesinhe, E.R., et al., "Taxus Callus Cultures: Initiation, Growth, Optimization, Characterization and Taxol Production", <i>Plant Cell, Tissue and Organ Culture</i> , 35, 181-193, (1993)
	C523	Wickremesinhe, E.R., et al., "Taxus Cell Suspension Cultures: Optimizing Growth and Production of Taxol", <i>J. Plant Physiol.</i> , 144, 183-188, (1994)
	C524	Wilensky, R.L., et al., "A Prospective, Randomized, Double-Blind, Dose-Escalation Study Evaluating the Safety and Tolerability of Cytochalasin B to Reduce Vascular Remodeling Following Percutaneous Transluminal Coronary Angioplasty", Abstract, 46 th Annual Scientific Session of the American College of Cardiology, 1 p., (1997)
	C525	Williams, J.K., et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", <i>Circulation</i> , 92, November 1995 AHA Meeting, (October 15, 1995)
	C526	Willson, T.M., et al., "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", <i>Endocrinology</i> , 138(9), (September 1997)
	C527	Winokur et al., "Expression of transforming growth factors β 1, 2, and 3 following vascular injury," <i>J. Cell Biochem., Suppl.</i> 15C:G414 (Abstr.) (1991)
	C528	Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", <i>Biochem. Soc. Symp.</i> , 61, 209-219, (1995)
	C529	Wiseman, L.R., et al., "Toremifene -- A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Advanced Breast Cancer", <i>Drugs</i> , 54, 141-160, (July 1997)
	C530	Witherup, K.M., et al., "Taxus Spp. Needles Contain Amounts of Taxol Comparable to the Bark of Taxus brevifolia: Analysis and Isolation", <i>Journal of Natural Products</i> , 53, 1249-1255, (Sep./Oct., 1990)
	C531	Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Beta1 Suppress Intimal Hyperplasia in a Rat Model", <i>J. Clin. Invest.</i> , 93, 1172-1178, (Mar. 1994)
	C532	Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", <i>Nature</i> , 370 341-347, (August 4, 1994)
	C533	Wright et al., "Percutaneous Endovascular Stents: An Experimental Study," <i>Radiology</i> 1984 Nov;153(P):206 Abs 593.
	C534	Wright et al., "Percutaneous Endovascular Stents: An Experimental Evaluation," <i>Radiology</i> 1985;1:69-72.
	C535	Wu et al., "Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation," <i>Transplant. Porc.</i> , 23:238-240 (1991)
	C536	Wu et al., "The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study," <i>J. Pharmacol. Sci.</i> 94:252-60 (2004)
	C537	Wu, et al., "Silicone-covered Self-expanding Metallic Stents for the Palliation of Malignant Esophageal Obstruction and Esophagorespiratory Fistulas: Experience in 32 Patients and a Review of the Literature," <i>Gastrointest. Endosc.</i> 1994; 40:22-33
	C538	Yamamoto et al., "Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease," <i>Circulation</i> , 102(11):1308-14 (2000)
	C539	Yang, N., et al., "Developing Particle-mediated Gene-transfer Technology for Research Into Gene Therapy of Cancer", <i>Molecular Medicine Today</i> , 476-481, (1996)
	C540	Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", <i>Calcified Tissue Intl.</i> , 54, 342, (1994)
	C541	Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17Beta-Estradiol and Raloxifene", <i>Science</i> , 273, 1222-1225, (Oct. 30, 1996)
	C542	Young H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", <i>Nucl. Med. Biol.</i> , 22, 405-411, (May 1995)
	C543	Zhang, L. et al., "MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized and tamoxifen-treated nude mice", <i>Oncogen</i> , 15, 2093-2108, (1997)
	C544	Ziegler, J. "Raloxifene, Retinoids, and Lavender: A Me Too@ Tamoxifen Alternatives Under Study", <i>Journal of the National Cancer Institute</i> , 88, 1100-1102, (1996)

	C545	Zohlhofer et al., "Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties," Mol. Pharmacol. 65:880-889 (2004)
	C546	Zuckerman, et al., "Cytokine Regulation of Macrophage apo E Secretion: Opposing Effects of GM-CSF and TGF- β ," Atherosclerosis, Vol. 96, pp. 203-214 (1992)
	C547	Zuckerman, et al., "Exogenous Glucocorticoids Increase Macrophage Secretion of E by Cholesterol-Independent Pathways," Atherosclerosis, Vol. 103, pp. 43-54 (1993)
	C548	Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Civil Action No. 03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C549	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 1, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C550	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 2, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C551	BSC's Answering Brief in Opposition to Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the '536 Patent
	C552	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art
	C553	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536
	C554	Complaint, Civil Action No. 03-283, Filed 3/13/03, U.S. District Court for the District of Delaware
	C555	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that Claims 6 and 8 of the Ding '536 Patent are Not Anticipated by the Asserted Prior Art
	C556	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536
	C557	Cordis' Answering <i>Markman</i> Brief on the Construction of Terms in the Ding '536 Patent
	C558	Declaration Of Brian G. Firth, Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C559	Declaration Of Dr. Jeffrey W. Moses, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C560	Declaration Of Dr. Martin B. Leon, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C561	Declaration Of Dr. Paul S. Teirstein, M.D., F.A.C.C., Civil Action No. 03-283 SLR, Dated 3/28/03, U.S. District Court for the District of Delaware
	C562	Declaration Of Dr. Peter Fitzgerald, M.D., Ph.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C563	Declaration Of Dr. Richard E. Kuntz, M.D. M.Sc., Civil Action No. 03-283 SLR, Dated 3/21/03, U.S. District Court for the District of Delaware
	C564	Declaration Of Eric Simso, Civil Action No. 03-283, Dated 3/20/03, U.S. District Court for the District of Delaware
	C565	Declaration Of Jermone Segal, M.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C566	Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C567	Defendants' Answer, Counterclaim And Demand For Jury Trial, Civil Action No. 03-283, Filed 4/7/03, U.S. District Court for the District of Delaware
	C568	Opening Expert Report Of Robson F. Storey, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C569	Opening Expert Report Of Stephen R. Hanson, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C570	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Opening Claim Construction Brief
	C571	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Rebuttal Claim Construction Brief
	C572	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art
	C573	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536 Patent
	C574	Plaintiffs' Opening Brief In Support Of Their Motion For Preliminary Injunction, Civil Action No. 03-283 Filed 3/20/03, U.S. District Court for the District of Delaware

	C575	Plaintiffs' Reply Brief In Support Of their Motion For Preliminary Injunction, Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	C576	Plaintiffs' Reply To Defendant's Counterclaim, Civil Action No. 03-283 Filed 4/21/03, U.S. District Court for the District of Delaware
	C577	Preliminary Injunction Hearing Transcript, Volume A, Civil Action No. 03-27 (SLR), Dated 7/21/03, U.S. District Court for the District of Delaware
	C578	Preliminary Injunction Hearing Transcript, Volume B, Civil Action No. 03-27 (SLR), Dated 7/22/03, U.S. District Court for the District of Delaware
	C579	Preliminary Injunction Hearing Transcript, Volume C, Civil Action No. 03-27 (SLR), Dated 7/23/03, U.S. District Court for the District of Delaware
	C580	Rebuttal Expert Report Of Kiman Park. Ph.D., Civil Action No.03-283 SLR, Dated 6/2/03, U.S. District Court for the District of Delaware
	C581	Redacted Public Version: Cordis' Opening <i>Markman</i> Brief on the Construction of Terms in the Ding '536 Patent
	C582	Redacted Public Version: Opening Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent
	C583	Reply Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent
	C584	Second Declaration Of Jerome Segal, M.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	C585	Second Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	